Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctioncysteine-type deubiquitinase activity

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

9.83e-1611423018GO:0004843
GeneOntologyMolecularFunctiondeubiquitinase activity

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

4.55e-1512423018GO:0101005
GeneOntologyMolecularFunctionubiquitin-like protein peptidase activity

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.73e-1413723018GO:0019783
GeneOntologyMolecularFunctioncysteine-type peptidase activity

USP17L7 USP17L21 USP17L1 USP17L20 SCRN1 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 TRHDE USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

8.77e-1419223020GO:0008234
GeneOntologyMolecularFunctionpeptidase activity

USP17L7 USP17L21 USP17L1 USP17L20 SCRN1 ERMP1 USP17L19 USP17L18 USP17L17 USP7 USP17L3 BACE2 USP47 USP17L13 TRHDE USP17L12 NPEPPS USP17L11 USP17L24 USP17L5 USP17L10 TLL1 USP17L22 USP17L15

6.08e-0765423024GO:0008233
GeneOntologyBiologicalProcessprotein deubiquitination

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.61e-1512522818GO:0016579
GeneOntologyBiologicalProcessprotein modification by small protein removal

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

3.30e-1414422818GO:0070646
GeneOntologyBiologicalProcessprotein modification by small protein conjugation or removal

USP17L7 USP17L21 USP17L1 USP17L20 CUL9 USP17L19 FEM1C ZZEF1 FBXL21P AXIN1 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 CUL4A TRIM2 USP17L12 NPEPPS USP17L11 USP17L24 USP17L5 MARCHF7 USP17L10 TRIM23 CEP63 LMO7 KLHL36 PRKCG BEX4 TRIM40 TOPORS USP17L22 USP17L15

1.80e-09100922835GO:0070647
GeneOntologyBiologicalProcesspost-translational protein modification

USP17L7 USP17L21 USP17L1 USP17L20 CUL9 USP17L19 FEM1C ZZEF1 FBXL21P AXIN1 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 CUL4A TRIM2 USP17L12 NPEPPS USP17L11 USP17L24 USP17L5 MARCHF7 USP17L10 TRIM23 CEP63 LMO7 KLHL36 PRKCG BEX4 TRIM40 TOPORS USP17L22 USP17L15

8.96e-09107422835GO:0043687
GeneOntologyBiologicalProcesshomophilic cell adhesion via plasma membrane adhesion molecules

DCHS2 FAT1 MYPN PCDH15 DSG1 PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 DCHS1 PCDH8 PCDHGA8

1.21e-0618722812GO:0007156
GeneOntologyBiologicalProcessnegative regulation of protein depolymerization

SPTA1 SPTBN1 SPTBN5 CLASP1 CAPG DBNL APC AVIL

6.45e-06892288GO:1901880
GeneOntologyBiologicalProcessactin filament depolymerization

SPTA1 SPTBN1 SPTBN5 CAPG DBNL MICAL2 AVIL

8.23e-06662287GO:0030042
GeneOntologyBiologicalProcessactin filament capping

SPTA1 SPTBN1 SPTBN5 CAPG DBNL AVIL

1.11e-05462286GO:0051693
GeneOntologyBiologicalProcessnegative regulation of protein-containing complex disassembly

SPTA1 SPTBN1 SPTBN5 CLASP1 CAPG DBNL APC AVIL

1.53e-051002288GO:0043242
GeneOntologyBiologicalProcessregulation of protein depolymerization

SPTA1 SPTBN1 SPTBN5 CLASP1 CAPG DBNL APC AVIL

2.19e-051052288GO:1901879
GeneOntologyBiologicalProcessnegative regulation of actin filament depolymerization

SPTA1 SPTBN1 SPTBN5 CAPG DBNL AVIL

2.27e-05522286GO:0030835
GeneOntologyBiologicalProcessprotein depolymerization

SPTA1 SPTBN1 SPTBN5 CLASP1 CAPG DBNL APC MICAL2 AVIL

3.29e-051442289GO:0051261
GeneOntologyBiologicalProcessregulation of actin filament depolymerization

SPTA1 SPTBN1 SPTBN5 CAPG DBNL AVIL

5.71e-05612286GO:0030834
GeneOntologyBiologicalProcessnegative regulation of protein polymerization

SPTA1 SPTBN1 SPTBN5 TBCD CAPG DBNL AVIL

6.77e-05912287GO:0032272
GeneOntologyBiologicalProcessnegative regulation of actin filament polymerization

SPTA1 SPTBN1 SPTBN5 CAPG DBNL AVIL

1.82e-04752286GO:0030837
GeneOntologyBiologicalProcesscell-cell adhesion via plasma-membrane adhesion molecules

DCHS2 FAT1 MYPN PCDH15 DSG1 PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 DCHS1 PCDH8 PCDHGA8

2.01e-0431322812GO:0098742
GeneOntologyBiologicalProcessregulation of protein-containing complex disassembly

SPTA1 SPTBN1 SPTBN5 CLASP1 CAPG DBNL APC AVIL

2.04e-041442288GO:0043244
GeneOntologyBiologicalProcessglomerulus morphogenesis

PDGFRB MTSS1 CTNND1

2.06e-04112283GO:0072102
GeneOntologyCellularComponentspectrin

SPTA1 SPTBN1 SPTBN5 EPB41L2

1.72e-0692304GO:0008091
GeneOntologyCellularComponentcell leading edge

PDGFRB SPTBN1 MTSS1 ADGRV1 FAT1 SYNJ2 MKLN1 NHS CDC42BPG FLOT2 CAPG DBNL APBB2 APC AVIL CTNND1 ARHGAP45

4.19e-0550023017GO:0031252
GeneOntologyCellularComponentcell cortex

SPTA1 SPTBN1 AXIN1 SPTBN5 EXOC3L4 MKLN1 FLOT2 CLASP1 DBNL APC KIAA1614 AKAP13 CTNND1 EPB41L2

6.74e-0537123014GO:0005938
GeneOntologyCellularComponentcortical actin cytoskeleton

SPTA1 SPTBN1 SPTBN5 FLOT2 DBNL AKAP13 EPB41L2

7.56e-05932307GO:0030864
GeneOntologyCellularComponentcortical cytoskeleton

SPTA1 SPTBN1 SPTBN5 FLOT2 CLASP1 DBNL AKAP13 EPB41L2

9.25e-051292308GO:0030863
GeneOntologyCellularComponentanchoring junction

DCHS2 PDGFRB MTSS1 ITGA7 FNDC1 FAT1 NHS TBCD FLOT2 DSG1 CLASP1 DBNL APC LIMS4 PDLIM5 LIMS3 SLC5A1 PLEKHG4B LMO7 AVIL PRKCG CTNND1 EPB41L2

5.03e-0497623023GO:0070161
GeneOntologyCellularComponentIRE1-TRAF2-ASK1 complex

ERN1 ERN2

7.13e-0442302GO:1990604
DomainHABP4_PAI-RBP1

USP17L7 USP17L21 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L22

5.77e-231623013PF04774
DomainHABP4_PAIRBP1-bd

USP17L7 USP17L21 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L22

5.77e-231623013IPR006861
DomainUSP_CS

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22

2.80e-186623017IPR018200
DomainUCH

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22

1.09e-177123017PF00443
DomainUSP_2

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22

1.09e-177123017PS00973
DomainUSP_3

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22

1.41e-177223017PS50235
DomainUSP_dom

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22

1.41e-177223017IPR028889
DomainPeptidase_C19_UCH

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22

1.41e-177223017IPR001394
DomainUSP_1

USP17L7 USP17L21 USP17L20 USP17L19 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22

2.28e-167023016PS00972
DomainCadherin_CS

DCHS2 FAT1 PCDH15 DSG1 PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 DCHS1 PCDH8 PCDHGA8

1.03e-0710923011IPR020894
DomainCADHERIN_1

DCHS2 FAT1 PCDH15 DSG1 PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 DCHS1 PCDH8 PCDHGA8

1.50e-0711323011PS00232
DomainCadherin

DCHS2 FAT1 PCDH15 DSG1 PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 DCHS1 PCDH8 PCDHGA8

1.50e-0711323011PF00028
DomainCADHERIN_2

DCHS2 FAT1 PCDH15 DSG1 PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 DCHS1 PCDH8 PCDHGA8

1.64e-0711423011PS50268
Domain-

DCHS2 FAT1 PCDH15 DSG1 PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 DCHS1 PCDH8 PCDHGA8

1.64e-07114230112.60.40.60
DomainCA

DCHS2 FAT1 PCDH15 DSG1 PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 DCHS1 PCDH8 PCDHGA8

1.80e-0711523011SM00112
DomainCadherin-like

DCHS2 FAT1 PCDH15 DSG1 PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 DCHS1 PCDH8 PCDHGA8

1.97e-0711623011IPR015919
DomainCadherin

DCHS2 FAT1 PCDH15 DSG1 PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 DCHS1 PCDH8 PCDHGA8

2.34e-0711823011IPR002126
DomainPQQ

ERN1 ERN2 ZNF106

3.59e-0562303SM00564
DomainPQQ_repeat

ERN1 ERN2 ZNF106

3.59e-0562303IPR002372
DomainPQQ_beta_propeller_repeat

ERN1 ERN2 ZNF106

3.59e-0562303IPR018391
DomainSCAN

ZSCAN26 ZNF202 ZSCAN1 ZSCAN2 SCAND2P ZNF263

6.34e-05562306SM00431
DomainSCAN_BOX

ZSCAN26 ZNF202 ZSCAN1 ZSCAN2 SCAND2P ZNF263

7.75e-05582306PS50804
DomainSCAN

ZSCAN26 ZNF202 ZSCAN1 ZSCAN2 SCAND2P ZNF263

7.75e-05582306PF02023
DomainSCAN_dom

ZSCAN26 ZNF202 ZSCAN1 ZSCAN2 SCAND2P ZNF263

7.75e-05582306IPR003309
DomainCadherin_tail

PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 PCDHGA8

8.57e-05372305PF15974
DomainCadherin_CBD

PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 PCDHGA8

8.57e-05372305IPR031904
DomainCadherin_2

PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 PCDH8 PCDHGA8

1.47e-04652306PF08266
DomainCadherin_N

PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 PCDH8 PCDHGA8

1.47e-04652306IPR013164
DomainDUF4757

LMO7 LIMCH1

1.51e-0422302PF15949
DomainCore_histone_macro-H2A

MACROH2A2 MACROH2A1

1.51e-0422302IPR021171
DomainDUF4757

LMO7 LIMCH1

1.51e-0422302IPR031865
Domain-

SEC23A CAPG DBNL AVIL

1.96e-042423043.40.20.10
DomainADF-H/Gelsolin-like_dom

SEC23A CAPG DBNL AVIL

1.96e-04242304IPR029006
DomainLIM

LIMS4 PDLIM5 LIMS3 LMO7 MICAL2 LIMCH1

2.05e-04692306PF00412
DomainLIM

LIMS4 PDLIM5 LIMS3 LMO7 MICAL2 LIMCH1

2.40e-04712306SM00132
DomainZnf_LIM

LIMS4 PDLIM5 LIMS3 LMO7 MICAL2 LIMCH1

2.40e-04712306IPR001781
DomainLIM_DOMAIN_1

LIMS4 PDLIM5 LIMS3 LMO7 MICAL2 LIMCH1

2.40e-04712306PS00478
DomainLIM_DOMAIN_2

LIMS4 PDLIM5 LIMS3 LMO7 MICAL2 LIMCH1

2.40e-04712306PS50023
Domain-

SPTBN1 SPTBN5 CEP95 LMO7 MICAL2 LIMCH1

2.40e-047123061.10.418.10
DomainCH-domain

SPTBN1 SPTBN5 CEP95 LMO7 MICAL2 LIMCH1

3.24e-04752306IPR001715
DomainKEN_dom

ERN1 ERN2

4.49e-0432302IPR010513
DomainPQQ

ERN1 ERN2

4.49e-0432302PF01011
DomainRibonuc_2-5A

ERN1 ERN2

4.49e-0432302PF06479
DomainKEN

ERN1 ERN2

4.49e-0432302PS51392
DomainGelsolin

SEC23A CAPG AVIL

6.07e-04142303PF00626
DomainGelsolin-like_dom

SEC23A CAPG AVIL

6.07e-04142303IPR007123
DomainRetrov_capsid_C

ZSCAN26 ZNF202 ZSCAN1 ZSCAN2 ZNF263

7.90e-04592305IPR008916
DomainBcl2-/adenovirus-E1B

PRUNE2 BNIPL

8.91e-0442302IPR022181
DomainBNIP2

PRUNE2 BNIPL

8.91e-0442302PF12496
DomainTaxilin

TXLNGY TXLNB

8.91e-0442302PF09728
DomainHEAT_type_2

DOHH DNAAF5 CLASP1

1.10e-03172303IPR021133
DomainZF_DAG_PE_1

DGKH CDC42BPG AKAP13 PRKCG ARHGAP45

1.15e-03642305PS00479
DomainZF_DAG_PE_2

DGKH CDC42BPG AKAP13 PRKCG ARHGAP45

1.15e-03642305PS50081
Domain-

SPTBN1 DGKH SPTBN5 MTMR3 PHLPP1 CDC42BPG APBB2 GRB10 PLEKHG4B SPRED1 AKAP13 EPB41L2 PHLPP2

1.17e-03391230132.30.29.30
DomainC1

DGKH CDC42BPG AKAP13 PRKCG ARHGAP45

1.23e-03652305SM00109
DomainCH

SPTBN1 SPTBN5 LMO7 MICAL2 LIMCH1

1.23e-03652305SM00033
DomainPE/DAG-bd

DGKH CDC42BPG AKAP13 PRKCG ARHGAP45

1.32e-03662305IPR002219
DomainPUG

ERN1 ERN2

1.47e-0352302SM00580
DomainDMAP_binding

DIP2A DIP2C

1.47e-0352302PF06464
Domain-

LIMS4 PDLIM5 LMO7 MICAL2 LIMCH1

1.71e-037023052.10.110.10
DomainCH

SPTBN1 SPTBN5 LMO7 MICAL2 LIMCH1

1.71e-03702305PF00307
DomainSAM_2

SAMD9 DGKH SASH3 ASZ1

1.90e-03432304PF07647
DomainARM-like

DOHH CUL9 UNC45A DNAAF5 TBCD HOMEZ CLASP1 APC CTNND1 PPP6R2

1.96e-0327023010IPR011989
DomainCH

SPTBN1 SPTBN5 LMO7 MICAL2 LIMCH1

2.06e-03732305PS50021
DomainCRAL_TRIO

CLVS2 PRUNE2 BNIPL

2.08e-03212303PF00650
DomainDMAP1-bd

DIP2A DIP2C

2.19e-0362302IPR010506
DomainPUB_domain

ERN1 ERN2

2.19e-0362302IPR018997
DomainHaem_d1

KMT2A STXBP5

2.19e-0362302IPR011048
Domain-

ERN1 ERN2

2.19e-03623022.140.10.10
DomainQuinoprotein_ADH-like_fam

ERN1 ERN2

2.19e-0362302IPR027295
DomainTyr_kinase_CSF1/PDGF_rcpt

PDGFRB FLT3

2.19e-0362302IPR016243
DomainDMAP_binding

DIP2A DIP2C

2.19e-0362302SM01137
DomainPH_dom-like

SPTBN1 DGKH SPTBN5 MTMR3 PHLPP1 CDC42BPG APBB2 GRB10 PLEKHG4B SPRED1 AKAP13 EPB41L2 PHLPP2

2.49e-0342623013IPR011993
PathwayREACTOME_RAS_PROCESSING

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

5.97e-194515615MM15671
PathwayREACTOME_UB_SPECIFIC_PROCESSING_PROTEASES

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 AXIN1 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 MAT2B USP17L11 USP17L5 USP17L10 RUVBL1 USP17L22 USP17L15

2.70e-1419115620MM15289
PathwayREACTOME_UB_SPECIFIC_PROCESSING_PROTEASES

USP17L21 USP17L1 USP17L20 USP17L19 AXIN1 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 MAT2B USP17L11 USP17L24 USP17L5 USP17L10 RUVBL1 USP17L22 USP17L15

4.36e-1322115620M27578
PathwayREACTOME_DEUBIQUITINATION

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 AXIN1 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 MAT2B USP17L11 APC USP17L5 USP17L10 RUVBL1 USP17L22 USP17L15

1.17e-1226215621MM15286
PathwayREACTOME_DEUBIQUITINATION

USP17L21 USP17L1 USP17L20 USP17L19 AXIN1 USP17L18 USP17L17 USP7 USP17L3 USP47 USP17L13 USP17L12 MAT2B USP17L11 USP17L24 APC USP17L5 USP17L10 RUVBL1 USP17L22 USP17L15

1.48e-1129915621M27574
PathwayREACTOME_MAPK_FAMILY_SIGNALING_CASCADES

USP17L7 USP17L21 USP17L1 PDGFRB USP17L20 SPTA1 SPTBN1 USP17L19 USP17L18 SPTBN5 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 SPRED1 USP17L22 USP17L15

3.36e-1031815620MM15278
PathwayREACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION

USP17L7 USP17L21 DOHH USP17L1 USP17L20 SPTA1 SPTBN1 USP17L19 FEM1C FBXL21P DDX5 AXIN1 USP17L18 SPTBN5 USP17L17 USP7 USP17L3 SEC23A USP47 USP17L13 CUL4A USP17L12 MAT2B USP17L11 APC USP17L5 USP17L10 RUVBL1 LMO7 NUP93 TOPORS USP17L22 USP17L15

1.80e-05138915633MM15307
PathwayREACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION

USP17L21 DOHH CCDC8 USP17L1 USP17L20 SPTA1 SPTBN1 CUL9 USP17L19 FEM1C DDX5 AXIN1 USP17L18 SPTBN5 USP17L17 USP7 USP17L3 SEC23A USP47 USP17L13 CUL4A USP17L12 MAT2B USP17L11 USP17L24 APC USP17L5 USP17L10 RUVBL1 LMO7 NUP93 TOPORS USP17L22 USP17L15

2.46e-05147515634M19806
PathwayREACTOME_REGULATION_OF_NPAS4_MRNA_TRANSLATION

TNRC6B AGO4 NPAS4

1.06e-0491563M46436
PathwayREACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS

SPTA1 SPTBN1 SPTBN5

1.51e-04101563MM15112
PathwayREACTOME_REGULATION_OF_NPAS4_GENE_EXPRESSION

TNRC6B AGO4 NPAS4

3.50e-04131563M46434
Pubmed

DUB-1, a deubiquitinating enzyme with growth-suppressing activity.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

9.93e-2921236158622927
Pubmed

DUB-1A, a novel deubiquitinating enzyme subfamily member, is polyubiquitinated and cytokine-inducible in B-lymphocytes.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

9.93e-29212361514583620
Pubmed

DUB-2A, a new member of the DUB subfamily of hematopoietic deubiquitinating enzymes.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

9.93e-29212361511468161
Pubmed

The murine DUB-1 gene is specifically induced by the betac subunit of interleukin-3 receptor.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

9.93e-2921236158756639
Pubmed

Lymphocyte-specific murine deubiquitinating enzymes induced by cytokines.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

9.93e-29212361512447969
Pubmed

DUB-1, a fate determinant of dynein heavy chain in B-lymphocytes, is regulated by the ubiquitin-proteasome pathway.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

9.93e-29212361518980247
Pubmed

JAK2 is required for induction of the murine DUB-1 gene.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

3.10e-2822236159154835
Pubmed

DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

2.35e-2724236158995226
Pubmed

Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

5.84e-27252361521115691
Pubmed

Cdc25A and Dub3 in a high-stakes balancing act.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

1.27e-26332361620228807
Pubmed

Decabromodiphenyl ethane affects embryonic development by interfering with nuclear F-actin in zygotes and leads to cognitive and social disorders in offspring mice.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

1.37e-26262361535816173
Pubmed

The DUB/USP17 deubiquitinating enzymes: a gene family within a tandemly repeated sequence, is also embedded within the copy number variable beta-defensin cluster.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.39e-26342361620403174
Pubmed

DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.39e-26342361614699124
Pubmed

The DUB/USP17 deubiquitinating enzymes, a multigene family within a tandemly repeated sequence.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.39e-26342361615780755
Pubmed

USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.39e-26342361619188362
Pubmed

Unstable transmission of the RS447 human megasatellite tandem repetitive sequence that contains the USP17 deubiquitinating enzyme gene.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.39e-26342361611941478
Pubmed

Hyaluronan- and RNA-binding deubiquitinating enzymes of USP17 family members associated with cell viability.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.39e-26342361617109758
Pubmed

The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.39e-26342361620388806
Pubmed

Polyclonal and monoclonal antibodies specific for USP17, a proapoptotic deubiquitinating enzyme.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.39e-26342361620715989
Pubmed

Human megasatellite DNA RS447: copy-number polymorphisms and interspecies conservation.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.39e-2634236169806828
Pubmed

The ubiquitin-specific protease 17 is involved in virus-triggered type I IFN signaling.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.39e-26342361620368735
Pubmed

The RS447 human megasatellite tandem repetitive sequence encodes a novel deubiquitinating enzyme with a functional promoter.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.39e-26342361610936051
Pubmed

The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.39e-26342361621448158
Pubmed

Cytokine-regulated protein degradation by the ubiquitination system.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

4.37e-26352361616611142
Pubmed

Lys-63-specific deubiquitination of SDS3 by USP17 regulates HDAC activity.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

4.37e-26352361621239494
Pubmed

The deubiquitinating enzyme USP17 blocks N-Ras membrane trafficking and activation but leaves K-Ras unaffected.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

7.82e-26362361620147298
Pubmed

Minor Splicing Factors Zrsr1 and Zrsr2 Are Essential for Early Embryo Development and 2-Cell-Like Conversion.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

1.35e-25292361532527007
Pubmed

Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

1.37e-25372361620228808
Pubmed

DUX is a non-essential synchronizer of zygotic genome activation.

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

3.46e-21502361531806660
Pubmed

A central chaperone-like role for 14-3-3 proteins in human cells.

CCDC8 SPTBN1 UNC45A PAK6 ATXN1 SYNJ2 CEP95 KMT2A NHS CUL4A KIF13B FLOT2 CLASP1 DCP2 DBNL APC GRB10 DENND4C ZNF106 LMO7 AKAP13 PRKCG LIMCH1 NUP93 CTNND1 EPB41L2 TP53BP2

4.91e-118612362736931259
Pubmed

USP7 represses lineage differentiation genes in mouse embryonic stem cells by both catalytic and noncatalytic activities.

USP17L7 USP17L21 KATNAL2 USP17L1 USP17L20 MATN1 LCA5L USP17L19 USP17L18 CEACAM21 USP17L17 SASH3 MYPN USP7 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 HHIP USP17L22 USP17L15

2.86e-106742362337196079
Pubmed

A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.

USP17L21 USP17L20 USP17L19 USP17L18 DNAAF5 USP17L17 FLT3 USP17L12 USP17L11 PCDHA6 PCDHA4

6.16e-101192361128625976
Pubmed

FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia.

DCHS2 ERCC6 KDM5C SPTBN1 CEP76 DIP2A GNL2 USP7 KMT2A QARS1 CLASP1 NPEPPS MACROH2A1 TOE1 ZNF106 LMO7 LIMCH1 CTNND1

1.08e-084972361836774506
Pubmed

Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.

DCHS2 PDGFRB SPTBN1 CUL9 ZNF202 CMYA5 GFAP ME3 DIP2A MTMR3 MKLN1 USP7 BACE2 QARS1 USP47 APBB2 APC JAKMIP3 PDLIM5 DHX30 CEP63 LMO7 MICAL2 SPRED1 CERCAM BEX4 ANKRD24 EIF3C CABIN1

1.68e-0812852362935914814
Pubmed

Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.

BRPF3 TBRG4 KDM5C MTSS1 SCRN1 ERMP1 ADGRV1 BCOR FEM1C ZZEF1 AGO4 SYNJ2 SUPT6H CARNS1 HOMEZ KIAA1614 LMO7 NUP93

2.79e-085292361814621295
Pubmed

KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.

SPTA1 SPTBN1 SCRN1 GFAP DDX5 DIP2A C12orf50 USP7 KMT2A UQCRFS1 SEC23A UQCRFS1P1 SLC12A6 FLOT2 CLASP1 NPEPPS DBNL APC PDLIM5 DHX30 LMO7 MICAL2 IGHM PRKCG LIMCH1 EIF3C CTNND1 PPP6R2 EPB41L2 TP53BP2

4.76e-0814312363037142655
Pubmed

CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1.

USP17L7 USP17L1 USP7 USP17L3 USP17L15

1.48e-0719236528067227
Pubmed

Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.

TNRC6B DGKH ADGRV1 TTF1 DNAAF5 TMEM184A ATXN1 SYNJ2 SUPT6H MKLN1 MACROH2A2 TBCD CUL4A PRUNE2 SLC12A6 CDC42BPG ST7 NPEPPS APBB2 GRB10 MACROH2A1 PLEKHG4B MICAL2 TLL1 DIP2C AKAP13 ANKRD24 LIMCH1 CTNND1

3.76e-0714892362928611215
Pubmed

E-cadherin interactome complexity and robustness resolved by quantitative proteomics.

SPTBN1 UNC45A PAK6 STAT2 SYNJ2 NHS CAPG DBNL MACROH2A1 PDLIM5 DENND4C RUVBL1 LMO7 SPRED1 LIMCH1 CTNND1 TP53BP2

3.87e-075652361725468996
Pubmed

High Dub3 expression in mouse ESCs couples the G1/S checkpoint to pluripotency.

USP17L7 USP17L1 USP17L3 USP17L15

4.20e-0710236424207026
Pubmed

Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.

TBRG4 PDGFRB MRPL37 SPTBN1 UNC45A CMYA5 DDX5 SUPT6H GNL2 USP7 QARS1 SEC23A FLOT2 ANKFY1 DSG1 MAT2B DYNC2H1 NPEPPS DBNL MACROH2A1 TOE1 DHX30 MROH8 RUVBL1 EIF3C NUP93 CTNND1 EPB41L2

5.10e-0714252362830948266
Pubmed

Cell cycle-dependent expression of Dub3, Nanog and the p160 family of nuclear receptor coactivators (NCoAs) in mouse embryonic stem cells.

USP17L7 USP17L1 USP17L3 USP17L15

9.80e-0712236424695638
Pubmed

PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice.

PHLPP1 APC PHLPP2

1.23e-064236324530606
Pubmed

Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers.

SPTBN1 TNRC6B UNC45A DDX5 AXIN1 USP7 NHS UQCRFS1 QARS1 CUL4A CDC42BPG FLOT2 NPEPPS APC PDLIM5 DHX30 RUVBL1 LMO7 MICAL2 LIMCH1 NUP93 CTNND1 TOPORS PPP6R2 TP53BP2

1.52e-0612472362527684187
Pubmed

Defining the human deubiquitinating enzyme interaction landscape.

USP17L7 UNC45A FEM1C SUPT6H GNL2 USP7 PHLPP1 USP47 CUL4A KIF13B ANKFY1 DSG1 DYNC2H1 NPEPPS APC IGHM EIF3C NUP93 CTNND1 PPP6R2 GPN3 PHLPP2

1.65e-0610052362219615732
Pubmed

ES cell neural differentiation reveals a substantial number of novel ESTs.

USP17L7 USP17L1 USP17L3 USP17L15

1.96e-0614236411793228
Pubmed

Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.

SPTBN1 TNRC6B BCOR SEC23A KIF13B ANKFY1 CLASP1 NPEPPS APC MACROH2A1 JAKMIP3 ZNF263 DCHS1 PRKCG LIMCH1 CTNND1 CABIN1 PPP6R2 PCDH8 EPB41L2 TP53BP2

3.04e-069632362128671696
Pubmed

The histone variant macroH2A confers functional robustness to the intestinal stem cell compartment.

MACROH2A2 APC MACROH2A1

3.05e-065236328934364
Pubmed

SARS-CoV-2 uses Spike glycoprotein to control the host's anaerobic metabolism by inhibiting LDHB.

TBRG4 SPTBN1 USP7 QARS1 DHTKD1 SEC23A TBCD ANKFY1 CAPG MACROH2A1 DHX30 IGHM EIF3C NUP93 CTNND1 EPB41L2

4.68e-066072361639147351
Pubmed

USP7 inhibits Wnt/β-catenin signaling through promoting stabilization of Axin.

AXIN1 USP7 APC

6.08e-066236331519875
Pubmed

N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective.

MRPL37 TNRC6B UNC45A BCOR DDX5 GNL2 USP7 KMT2A FLOT2 DSG1 DBNL MACROH2A1 PDLIM5 DHX30 RUVBL1 EIF3C CTNND1 PPP6R2 EPB41L2 TP53BP2

6.89e-069342362033916271
Pubmed

Comparative DNA sequence analysis of mouse and human protocadherin gene clusters.

PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 PCDH8 PCDHGA8

7.06e-0668236611230163
Pubmed

A high-throughput approach for measuring temporal changes in the interactome.

MAN2B1 SPTBN1 UNC13D SCRN1 UNC45A CMYA5 ZZEF1 DDX5 DNAAF5 USP7 QARS1 SEC23A USP47 TBCD CUL4A PRUNE2 FKBP10 ANKFY1 MAT2B NPEPPS DBNL PDLIM5 RUVBL1 LIMCH1 EIF3C EPB41L2

7.38e-0614552362622863883
Pubmed

Ubiquitin-Independent Disassembly by a p97 AAA-ATPase Complex Drives PP1 Holoenzyme Formation.

SPTBN1 DDX5 SUPT6H MYPN USP7 APC DHX30 RUVBL1 LMO7 AKAP13 DDX28 EPB41L2

7.65e-063612361230344098
Pubmed

A striking organization of a large family of human neural cadherin-like cell adhesion genes.

PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 PCDH8 PCDHGA8

9.85e-0672236610380929
Pubmed

A probability-based approach for high-throughput protein phosphorylation analysis and site localization.

TBRG4 ERCC6 KDM5C MYPN NHS USP47 DBNL APC GRB10 DENND4C LMO7 AKAP13 EIF3C EPB41L2

1.02e-055032361416964243
Pubmed

Expression of mouse dchs1, fjx1, and fat-j suggests conservation of the planar cell polarity pathway identified in Drosophila.

DCHS2 FAT1 DCHS1

1.06e-057236316059920
Pubmed

The PHLPP1 N-Terminal Extension Is a Mitotic Cdk1 Substrate and Controls an Interactome Switch.

UNC45A MYPN PHLPP1 APC DENND4C RUVBL1 LMO7 LIMCH1 CTNND1 EPB41L2

1.11e-052562361033397691
Pubmed

Cadherin superfamily genes: functions, genomic organization, and neurologic diversity.

PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 PCDH8 PCDHGA8

1.15e-0574236610817752
Pubmed

Interactomes of Glycogen Synthase Kinase-3 Isoforms.

TNRC6B AXIN1 MYPN NHS CLASP1 APC DENND4C CTNND1 TP53BP2

1.42e-05209236936779422
Pubmed

Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members.

PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 PCDH8 PCDHGA8

1.45e-0577236610835267
Pubmed

The N6-methyladenosine-mediated lncRNA WEE2-AS1 promotes glioblastoma progression by stabilizing RPN2.

DOHH SPTBN1 SCRN1 DNAAF5 SEC23A TBCD FKBP10 CLASP1 GRB10 DHX30 CTNND1

1.56e-053252361136168628
Pubmed

Large exons encoding multiple ectodomains are a characteristic feature of protocadherin genes.

PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 PCDH8 PCDHGA8

1.81e-0580236610716726
Pubmed

TRIM24 is an insulin-responsive regulator of P-bodies.

SPTBN1 TNRC6B AGO4 DSG1 MACROH2A1 DHX30

1.81e-0580236635803934
Pubmed

Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.

ERCC6 CENPC SPTBN1 UNC45A DDX5 USP7 MACROH2A2 QARS1 SEC23A ANKFY1 DSG1 NPEPPS DBNL MACROH2A1 TOE1 DHX30 RUVBL1 MICAL2 MRPS23 AKAP13 NUP93 CTNND1 EPB41L2 TP53BP2

1.91e-0513532362429467282
Pubmed

Human and mouse proteases: a comparative genomic approach.

USP17L7 USP17L1 USP7 USP17L3 USP47 USP17L15

1.94e-0581236612838346
Pubmed

A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration.

TNRC6B CEP76 BCOR PTPRN ATXN1 USP7 MARCHF7 MACROH2A1 PDLIM5 IGHM PRKCG PPP6R2 PCDH8 EPB41L2 TP53BP2

2.02e-056082361516713569
Pubmed

The Hsp70-Hsp90 co-chaperone Hop/Stip1 shifts the proteostatic balance from folding towards degradation.

SPTBN1 UNC45A DDX5 DNAAF5 SUPT6H USP7 QARS1 SEC23A CCDC117 ANKFY1 DHX30 RUVBL1 EIF3C NUP93 EPB41L2

3.50e-056382361533239621
Pubmed

LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells.

CCDC8 SPTBN1 CUL9 DGKH CEP76 DDX5 FAT1 SUPT6H KMT2A DSG1 APC RUVBL1 MRPS23 CTNND1 PPP6R2

3.57e-056392361523443559
Pubmed

Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD.

KMT2A FLT3

4.59e-052236227881871
Pubmed

p120-Catenin is an obligate haploinsufficient tumor suppressor in intestinal neoplasia.

APC CTNND1

4.59e-052236229130932
Pubmed

Long non‑coding RNA HHIP‑AS1 inhibits lung cancer epithelial‑mesenchymal transition and stemness by regulating PCDHGA9.

PCDHGA9 HHIP

4.59e-052236234643245
Pubmed

Nup93 regulates breast tumor growth by modulating cell proliferation and actin cytoskeleton remodeling.

LIMCH1 NUP93

4.59e-052236231959624
Pubmed

Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling.

UQCRFS1 UQCRFS1P1

4.59e-052236223415911
Pubmed

A mild impairment of mitochondrial electron transport has sex-specific effects on lifespan and aging in mice.

UQCRFS1 UQCRFS1P1

4.59e-052236222028811
Pubmed

Macro histone variants are critical for the differentiation of human pluripotent cells.

MACROH2A2 MACROH2A1

4.59e-052236223595991
Pubmed

Cloning, genomic organization and expression pattern of a novel Drosophila gene, the disco-interacting protein 2 (dip2), and its murine homolog.

DIP2A DIP2C

4.59e-052236212137943
Pubmed

The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule.

ERN1 ERN2

4.59e-052236222315414
Pubmed

Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.

KMT2A FLT3

4.59e-052236224085765
Pubmed

PHLPP isoforms differentially regulate Akt isoforms and AS160 affecting neuronal insulin signaling and insulin resistance via Scribble.

PHLPP1 PHLPP2

4.59e-052236236376971
Pubmed

Targeting the NAD+ salvage pathway suppresses APC mutation-driven colorectal cancer growth and Wnt/β-catenin signaling via increasing Axin level.

AXIN1 APC

4.59e-052236232005247
Pubmed

Trisomy 11 in myeloid malignancies is associated with internal tandem duplication of both MLL and FLT3 genes.

KMT2A FLT3

4.59e-052236215710585
Pubmed

PHLPPing through history: a decade in the life of PHLPP phosphatases.

PHLPP1 PHLPP2

4.59e-052236227913677
Pubmed

Membrane domain organization of myelinated axons requires βII spectrin.

SPTBN1 AVIL

4.59e-052236224217619
Pubmed

Genetic alterations in members of the Wnt pathway in acute leukemia.

AXIN1 APC

4.59e-052236221902576
Pubmed

Translational control by the ER transmembrane kinase/ribonuclease IRE1 under ER stress.

ERN1 ERN2

4.59e-052236211175748
Pubmed

Endoplasmic reticulum stress in the regulation of liver diseases: Involvement of Regulated IRE1α and β-dependent decay and miRNA.

ERN1 ERN2

4.59e-052236227774654
Pubmed

Structural basis of the Axin-adenomatous polyposis coli interaction.

AXIN1 APC

4.59e-052236210811618
Pubmed

Characterization of two homologs of Ire1p, a kinase/endoribonuclease in yeast, in Arabidopsis thaliana.

ERN1 ERN2

4.59e-052236212020828
Pubmed

Ras-associating domain proteins: a new class of cyclic nucleotide-gated channel modulators.

PHLPP1 PHLPP2

4.59e-052236222183406
Pubmed

STAT2 Controls Colorectal Tumorigenesis and Resistance to Anti-Cancer Drugs.

STAT2 APC

4.59e-052236238001683
Pubmed

Histone macroH2A isoforms predict the risk of lung cancer recurrence.

MACROH2A2 MACROH2A1

4.59e-052236219648962
Pubmed

Expression of USP7 and MARCH7 Is Correlated with Poor Prognosis in Epithelial Ovarian Cancer.

USP7 MARCHF7

4.59e-052236227302477
Pubmed

FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.

KMT2A FLT3

4.59e-052236233623141
Pubmed

Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.

KMT2A FLT3

4.59e-052236222674806
Pubmed

Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.

KMT2A FLT3

4.59e-052236223660685
Pubmed

Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

KMT2A FLT3

4.59e-052236228108543
Pubmed

Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group.

KMT2A FLT3

4.59e-052236217763464
Pubmed

Biochemical characterization of the phosphatase domain of the tumor suppressor PH domain leucine-rich repeat protein phosphatase.

PHLPP1 PHLPP2

4.59e-052236224892992
Pubmed

MACROH2A2, a new member of the MARCOH2A core histone family.

MACROH2A2 MACROH2A1

4.59e-052236211262398
InteractionFLT3 interactions

USP17L21 USP17L20 USP17L19 USP17L18 DNAAF5 USP17L17 KMT2A QARS1 FLT3 USP17L12 NPEPPS USP17L11 PCDHA6 PCDHA4 MACROH2A1 DHX30 NUP93

1.49e-0731822917int:FLT3
InteractionOVOL2 interactions

UNC45A ZZEF1 DDX5 USP7 MACROH2A1 RUVBL1 LMO7 KLHL36 NUP93 CTNND1

1.93e-0612722910int:OVOL2
InteractionFBXO22 interactions

DCHS2 ERCC6 KDM5C SPTBN1 CEP76 DIP2A GNL2 USP7 PHLPP1 KMT2A QARS1 CLASP1 NPEPPS MACROH2A1 TOE1 ZNF106 LMO7 LIMCH1 CTNND1

1.42e-0554022919int:FBXO22
InteractionPCDHGA8 interactions

PCDHGA9 PCDHGA5 PCDHGA8

1.42e-0552293int:PCDHGA8
Cytoband4p16.1

USP17L21 USP17L20 USP17L19 USP17L18 USP17L17 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.45e-1679236134p16.1
CytobandEnsembl 112 genes in cytogenetic band chr4p16

USP17L21 USP17L20 USP17L19 USP17L18 USP17L17 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

1.74e-1022223613chr4p16
Cytoband5q31

FBXL21P PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 PCDHGA8

3.05e-0511523665q31
GeneFamilyCadherin related

DCHS2 FAT1 PCDH15 DCHS1

9.96e-0617150424
GeneFamilyEF-hand domain containing|Spectrins

SPTA1 SPTBN1 SPTBN5

1.91e-05715031113
GeneFamilyLIM domain containing

PDLIM5 LIMS3 LMO7 MICAL2 LIMCH1

1.28e-045915051218
GeneFamilyClustered protocadherins

PCDHGA9 PCDHGA5 PCDHA6 PCDHA4 PCDHGA8

1.89e-0464150520
GeneFamilyPleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing

SPTBN1 DGKH PHLPP1 CDC42BPG GRB10 PLEKHG4B AKAP13 PHLPP2

3.27e-042061508682
GeneFamilyLIM zinc finger domain containing|LIM domain containing

LIMS4 LIMS3

4.06e-04415021163
GeneFamilyRho GTPase activating proteins|BCH domain containing

PRUNE2 BNIPL

1.40e-03715021299
GeneFamilyGelsolin/villins

CAPG AVIL

1.85e-0381502950
GeneFamilyCullins

CUL9 CUL4A

1.85e-03815021032
GeneFamilyAnkyrin repeat domain containing

BCOR FEM1C ANKRD20A4P ANKFY1 ASZ1 ANKRD24 TP53BP2

4.12e-032421507403
CoexpressionMADAN_DPPA4_TARGETS

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

1.44e-158623415MM1312
CoexpressionGRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

8.47e-1411223415MM1095
CoexpressionGERY_CEBP_TARGETS

USP17L7 USP17L21 USP17L1 USP17L20 BCKDHB USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 USP17L12 USP17L11 USP17L5 USP17L10 USP17L22 USP17L15

1.27e-1216023416MM1155
CoexpressionGRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP

USP17L7 USP17L21 MAN2B1 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 USP17L13 CCDC117 CUL4A USP17L12 GAL3ST1 USP17L11 CAPG AOX1 USP17L5 USP17L10 PDLIM5 USP17L22 GPN3 USP17L15

2.18e-0864723423MM981
CoexpressionMARSON_BOUND_BY_FOXP3_STIMULATED

USP17L7 USP17L21 USP17L1 ERN1 CENPC TNFSF14 USP17L20 KDM5C P4HA3 USP17L19 USP17L18 TRAT1 USP17L17 ATXN1 SYNJ2 SASH3 SUPT6H USP17L3 USP17L13 CCDC117 USP17L12 MAT2B USP17L11 USP17L5 USP17L10 DNAI4 USP17L22 GPN3 USP17L15 EPB41L2

3.27e-08107223430MM1031
CoexpressionPARENT_MTOR_SIGNALING_UP

LYRM9 SAMD9 TNRC6B CUL9 DGKH UNC45A ITGA7 ME3 DIP2A ATXN1 SUPT6H USP47 NPEPPS CAPG DHX30 DNAI4 AKAP13 EIF3C CTNND1 CABIN1

2.13e-0756723420M16909
CoexpressionBRUINS_UVC_RESPONSE_LATE

USP17L7 USP17L21 DOHH USP17L1 USP17L20 USP17L19 USP17L18 CEACAM21 USP17L17 EXOC3L4 USP17L3 USP47 TBCD USP17L13 USP17L12 STXBP5 USP17L11 DBNL GRB10 USP17L5 USP17L10 RUVBL1 UTP11 NUP93 USP17L22 USP17L15

2.83e-05119823426MM1062
CoexpressionDACOSTA_UV_RESPONSE_VIA_ERCC3_DN

CENPC ZZEF1 FAT1 ATXN1 SYNJ2 MTMR3 MKLN1 USP7 PHLPP1 ATP13A3 TRIM2 CLASP1 NPEPPS APBB2 APC MARCHF7 PDLIM5 MICAL2 AKAP13 TP53BP2 PHLPP2

3.07e-0585623421M4500
ToppCellFibroblasts-DKK3+_Fibroblasts|Fibroblasts / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues

PDGFRB P4HA3 SCRN1 FNDC1 FAT1 SEC23A PRUNE2 CAPG MICAL2 CERCAM CA5B

6.04e-091962281124d64b67aa9b0e8215ad06f9101c1314b3483620
ToppCellChildren_(3_yrs)-Epithelial-club_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor

ADGRV1 ITGA9 FAT1 TMEM184A NHS TRIM2 ERN2 PLEKHG4B LMO7 TLL1

5.78e-081912281023776c7302cead3881b39127398f3b3e0d27885e
ToppCell10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

ERMP1 SYNJ2 CARNS1 TRIM2 GAL3ST1 JAKMIP3 ENPP4 HHIP CERCAM LIMCH1

6.69e-0819422810cb0422e7607dbd77204428b7e2c70dfe14a6ca11
ToppCell5'-GW_trimst-2-LargeIntestine-Epithelial-neuro-epithelial-EECs|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

DGKH ADGRV1 CFAP65 PTPRN KIAA2012 STXBP5 AOX1 PRKCG NPAS4

1.90e-0716522894b4e75ad0eb0a6b00c30a000ec6267e23ba2e496
ToppCell3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.5|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

DGKH ADGRV1 CMYA5 TMEM184A TRIM2 NPEPPS ERN2 LMO7 CTNND1

3.78e-0717922896e965e424eebef50f0202cff75f458be395cfca1
ToppCellControl_saline-Epithelial_alveolar-AT_1-AT1|Control_saline / Treatment groups by lineage, cell group, cell type

UNC13D FBP1 LIMS4 LMO7 CERCAM LIMCH1 BCAM DSEL TP53BP2

8.81e-0719822899f972f217d2c39d4c0f7d0d4227d0fffe8535b9d
ToppCellTracheal-NucSeq|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations

TNRC6B BCKDHB ATXN1 MKLN1 CLASP1 STXBP5 APBB2 DIP2C LIMCH1

9.18e-07199228994b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCellwk_15-18-Mesenchymal-Chondrocyte-ASPN+_chondrocyte|wk_15-18 / Celltypes from embryonic and fetal-stage human lung

LYRM9 MATN1 GFAP FNDC1 CEP95 MTMR3 KIAA1614 AVIL

3.91e-061782288a55130670aa95a87b833dd3cd2de461d779e4c06
ToppCellChildren_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor

ADGRV1 ITGA9 KIF13B TRIM2 ERN2 LMO7 BNIPL LIMCH1

3.91e-061782288f5ed4a6e3eb8056b1be1fb311021710c95bdf888
ToppCellChildren_(3_yrs)-Epithelial-club_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor

ADGRV1 ITGA9 FAT1 TMEM184A NHS TRIM2 ERN2 BNIPL

4.25e-061802288b509c7d6bdfba672065fb722874bdc68de72ba1c
ToppCellChildren_(3_yrs)-Epithelial-club_cell-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor

ITGA9 FAT1 TMEM184A TRIM2 ERN2 PLEKHG4B LMO7 TLL1

4.61e-061822288215c303df42f13597b2c7a95cb157c6bc7aca9a1
ToppCelldroplet-Heart-nan-3m-Endothelial|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SPTBN1 MTSS1 CPED1 APC LMO7 BEX4 LIMCH1 BCAM

5.41e-0618622880ae5fbe9f210cb25092394267e1d3d6ed05627b8
ToppCellAdult-Epithelial-club_cell-D231|Adult / Lineage, Cell type, age group and donor

ADGRV1 FAT1 NHS TRIM2 ERN2 PLEKHG4B TLL1 BNIPL

5.63e-061872288ee59d7d3de5879738ff0b9c3ea5e4847fb48cb86
ToppCellAdult-Epithelial-club_cell|Adult / Lineage, Cell type, age group and donor

ADGRV1 ITGA9 FAT1 NHS TRIM2 ERN2 PLEKHG4B TLL1

6.33e-061902288756bff697d30aec56c0ebfca94295f084a15bf37
ToppCellFetal_29-31_weeks-Mesenchymal-vascular_smooth_muscle_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

PDGFRB DGKH ITGA7 CPED1 FAT1 NHS PDLIM5 NPAS4

6.33e-061902288d6b3a92119b210974a32af3fe9875d60eb02761e
ToppCellCOVID-19-Epithelial_cells-Airway_goblet|COVID-19 / group, cell type (main and fine annotations)

ADGRV1 NHS BACE2 TRIM2 ERN2 SLC5A1 PLEKHG4B LMO7

6.33e-06190228851ca9ef4df3220487152fcf684147730637c7cc1
ToppCellChildren_(3_yrs)-Epithelial-club_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor

ADGRV1 ITGA9 FAT1 TRIM2 ERN2 PLEKHG4B LMO7 LIMCH1

7.65e-061952288dccc32fcf772e2504de7f663ef0a5bd8e23e92fc
ToppCellParenchymal-NucSeq-Epithelial-Epi_airway_secretory-Secretory_Club|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

ADGRV1 ITGA9 FAT1 NHS TRIM2 ERN2 PLEKHG4B LMO7

8.55e-0619822881408e02e053ad3406229bfe8189da03be6366e81
ToppCellControl_saline-Epithelial_alveolar-AT_1|Control_saline / Treatment groups by lineage, cell group, cell type

UNC13D FBP1 LMO7 CERCAM LIMCH1 BCAM DSEL TP53BP2

8.55e-0619822889b161285df7a4e51618f3517cfc5b8221ba55786
ToppCellControl_saline-Epithelial_alveolar-AT_1-Differentiating_AT1|Control_saline / Treatment groups by lineage, cell group, cell type

UNC13D FBP1 LMO7 CERCAM LIMCH1 BCAM DSEL TP53BP2

8.55e-06198228885f424cd9bb3117c9e322031024aabb87696ce47
ToppCell10x5'v1-week_14-16-Mesenchymal_osteo-stroma-osteoblast_precursor|week_14-16 / cell types per 3 fetal stages;per 3',per 5'

PDGFRB FNDC1 FAT1 FKBP10 DYNC2H1 LMO7 CERCAM LIMCH1

8.55e-061982288bc9c9f2c87282b5ef8514773e065d2a6b5dde338
ToppCellTracheal|World / Cell types per location group and 10X technology with lineage, and cell group designations

BCKDHB CMYA5 SYNJ2 NHS BACE2 TRIM2 ERN2 SLC5A1

9.20e-062002288682960e28542a3d6c119047cd0131941932cfdea
ToppCellMacroglial-Oligodendrocytes-OPALIN--|Macroglial / cells hierarchy compared to all cells using T-Statistic

SYNJ2 CARNS1 PRUNE2 KIF13B TRIM2 HHIP CERCAM LIMCH1

9.20e-06200228826b989e30bbbaf30904ced03f6aae3dea25c732c
ToppCell10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

SYNJ2 CARNS1 PRUNE2 TRIM2 GAL3ST1 HHIP CERCAM LIMCH1

9.20e-062002288159377d904394d91e09913131e9a93e08189955a
ToppCellMacroglial-Oligodendrocytes-OPALIN---|Macroglial / cells hierarchy compared to all cells using T-Statistic

SYNJ2 CARNS1 PRUNE2 KIF13B TRIM2 HHIP CERCAM LIMCH1

9.20e-0620022881314664c1721e9ecb1e2c3482a039044b0fe50a9
ToppCellMacroglial-Oligodendrocytes-OPALIN|Macroglial / cells hierarchy compared to all cells using T-Statistic

SYNJ2 CARNS1 PRUNE2 KIF13B TRIM2 HHIP CERCAM LIMCH1

9.20e-0620022885f75a9b8bcd49d9bbb1e9ce2de730eaec96369ca
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-F|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

SYNJ2 CARNS1 PRUNE2 TRIM2 ENPP4 HHIP CERCAM LIMCH1

9.20e-062002288829978708463a7459fe1041bd90196775bc4b531
ToppCellMacroglial-Oligodendrocytes|Macroglial / cells hierarchy compared to all cells using T-Statistic

SYNJ2 CARNS1 PRUNE2 KIF13B TRIM2 HHIP CERCAM LIMCH1

9.20e-0620022884dbac2f2587e87ca5a0622f50439bb5447e93c7f
ToppCell10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-F|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

DOHH SYNJ2 CARNS1 PRUNE2 TRIM2 HHIP CERCAM LIMCH1

9.20e-0620022883ce8a2db8c25e1169a0a544f644a63104749c5ee
ToppCellLPS_IL1RA-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

ITGA9 CPED1 FNDC1 FAT1 PRUNE2 FKBP10 HHIP NUP93

9.20e-0620022888988f113708eef7d9d2a6a6c1bcfd7c8f9804d3e
ToppCell10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

SYNJ2 CARNS1 PRUNE2 TRIM2 GAL3ST1 HHIP CERCAM LIMCH1

9.20e-0620022880bfd41c12887479ceb62c3db0a3c3ba5007eb62b
ToppCell10x_3'_v2v3-Non-neoplastic-Glial-Neuronal|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

SYNJ2 CARNS1 PRUNE2 TRIM2 GAL3ST1 HHIP CERCAM LIMCH1

9.20e-062002288d30316836494f33ca46d4e415fd2ed179e9cb5ee
ToppCellLPS_IL1RA_TNF-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

ITGA9 CPED1 FNDC1 FAT1 PRUNE2 FKBP10 HHIP NUP93

9.20e-062002288dcdaec3ca3a3024dc1b8788c417003f84c2bffdc
ToppCellMacroglial-Oligodendrocytes-OPALIN-|Macroglial / cells hierarchy compared to all cells using T-Statistic

SYNJ2 CARNS1 PRUNE2 KIF13B TRIM2 HHIP CERCAM LIMCH1

9.20e-0620022888b229f095fc113aecfc94b64862a9e0fdcc363ce
ToppCellMacroglial-Oligodendrocytes-OPALIN----L1-6|Macroglial / cells hierarchy compared to all cells using T-Statistic

SYNJ2 CARNS1 PRUNE2 KIF13B TRIM2 HHIP CERCAM LIMCH1

9.20e-062002288272909f4354f3ae22e2b2f8f35970e6b0e92cfe2
ToppCellwk_15-18-Mesenchymal-Myofibro_&_SMC-Myofibro_2|wk_15-18 / Celltypes from embryonic and fetal-stage human lung

CMYA5 ITGA9 CPED1 FAT1 NHS FKBP10 HHIP

1.67e-051572287b9d04ee417c0d8ea0801d10f1c54e138587009fd
ToppCellnormal_Pleural_Fluid-T/NK_cells-CD4+_Th|normal_Pleural_Fluid / Location, Cell class and cell subclass

DIP2A ANKRD20A4P NHS TBCD KIAA1614 DNAI4 CA5B

1.82e-051592287ebd840ac2b07e62086ee7b5bb01c21804a0fdc7b
ToppCellnormal_Lung-Fibroblasts-Myofibroblasts|Fibroblasts / Location, Cell class and cell subclass

P4HA3 FNDC1 ZSCAN1 PTPRN MOV10L1 PLEKHG4B MICAL2

2.22e-0516422879b4a6007abae992db871d9f6f731d5af724de30d
ToppCellAdult-Epithelial-lung_goblet_cell-D122|Adult / Lineage, Cell type, age group and donor

CYP8B1 ZSCAN1 TMEM184A NHS ERN2 PLEKHG4B TLL1

2.49e-0516722876efbb2ef6adc8da5dd67210969f825f5cc8ed022
ToppCell3'-Broncho-tracheal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.0.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

DGKH CFAP65 CAPS2 KIAA2012 DYNC2H1 DNAH2 DNAI4

2.69e-05169228714aadc2d1bf66eb47dac33b4d61ddb3c942caa4f
ToppCellLV-13._Vascular_Smooth_Muscle|LV / Chamber and Cluster_Paper

PDGFRB DGKH NHS PRUNE2 APBB2 BCAM NPAS4

2.90e-051712287e99ecae66530d1ae09330cee408c8f3950b87e67
ToppCellChildren_(3_yrs)-Epithelial-lung_goblet_cell-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor

DCHS2 CLVS2 NHS ERN2 SLC5A1 PLEKHG4B TLL1

3.12e-051732287464267a2ff3f5c387b6c9c6fa4dab135a221f448
ToppCelldroplet-Limb_Muscle-MUSCLE-1m-Lymphocytic-unknown|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ERN1 UNC13D GFAP ETAA1 NUDT7 DDX28 PHLPP2

3.24e-0517422876987fe7959afce347282f632abc16d800ccab7c4
ToppCellFetal_29-31_weeks-Mesenchymal-vascular_smooth_muscle_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

PDGFRB DGKH ITGA7 CPED1 FAT1 NHS GRB10

3.24e-051742287015d3742d3d79a57413a333f00ef2d380a9848dd
ToppCellP15-Epithelial-epithelial_progenitor_cell-epithelial_unknown_3|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

ERCC6 GFAP NHS GAL3ST1 CAPG TOE1 SPRED1

3.49e-051762287792f414f5092aba14260b8e16378e793a822498e
ToppCellTCGA-Brain-Primary_Tumor-Low_Grade_Glioma|TCGA-Brain / Sample_Type by Project: Shred V9

TNRC6B MTMR3 PHLPP1 KMT2A DHTKD1 USP47 DIP2C

3.61e-051772287e8ab340b20cd41554c3841fe980e078e878af35f
ToppCellAdult-Epithelial-lung_goblet_cell|Adult / Lineage, Cell type, age group and donor

DCHS2 NHS BACE2 ERN2 SLC5A1 PLEKHG4B TLL1

3.88e-0517922871fc1f252ca943a2f649d1e627f56acbf15f8e058
ToppCellfacs-Lung-24m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

TTF1 CEP95 ATP13A3 APBB2 TXLNB DCHS1 DDX28

4.02e-0518022872d608b9394d28d19cfc85c6ac94003d5177c8a92
ToppCellfacs-Lung-24m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell-pulmonary_artery_endothelial_cell_l25|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

TTF1 CEP95 ATP13A3 APBB2 TXLNB DCHS1 DDX28

4.02e-051802287baa5825e6ce23a98d9c21d024a4b0ab8ba353d0c
ToppCellfacs-Lung-24m-Endothelial-arterial_endothelial|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

TTF1 CEP95 ATP13A3 APBB2 TXLNB DCHS1 DDX28

4.02e-0518022870f9b27054358c4737eed06c8ea01987cccc3cb55
ToppCellLV-15._Ventricular_Cardiomyocyte_III|LV / Chamber and Cluster_Paper

CMYA5 CPED1 MYPN PDLIM5 LMO7 AKAP13 LIMCH1

4.62e-051842287ab7a1620c14a9d9b6be1b47c559931e345e9eef8
ToppCellChildren_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor

ADGRV1 ITGA9 FAT1 NUDT7 TRIM2 LMO7 LIMCH1

4.62e-051842287102105ae1a5ef6d42a43f6d9b00f12ed0690ddb7
ToppCellmild-Myeloid-mDC|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs

SCRN1 CPED1 FBP1 FLT3 CAPG MACROH2A1 EPB41L2

4.62e-0518422878b37c00d59d9992d3b43268991da7bb94646c70e
ToppCellSmart-seq2-tissue-resident_(Smart-seq2)-myeloid-myeloid_granulocytic-mast_cell|tissue-resident_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type

ITGA9 BACE2 KIF13B CAPG PDLIM5 DIP2C AKAP13

4.78e-0518522873fafb1d36c5f98a29d20a5ce5192c83d6f603514
ToppCellChildren_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)|Children_(3_yrs) / Lineage, Cell type, age group and donor

ADGRV1 ITGA9 FAT1 TRIM2 LMO7 BNIPL LIMCH1

4.78e-05185228798b8ee42b89d97e4c9db01740e0c193503c68f2c
ToppCellLV-15._Ventricular_Cardiomyocyte_III|World / Chamber and Cluster_Paper

CMYA5 CPED1 MYPN PDLIM5 SLC5A1 LMO7 LIMCH1

4.78e-0518522876baccb26f999145e51b91d94315bf8d4655bef31
ToppCellLPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

UNC13D ADGRV1 ITGA9 PLEKHG4B LMO7 LIMCH1 BCAM

5.12e-05187228758d48128547ee3513d0bf7f78e61b76b1c472ca9
ToppCellLV-04._Ventricular_Cardiomyocyte_I|World / Chamber and Cluster_Paper

CMYA5 CPED1 SLC5A1 TXLNB LMO7 LIMCH1 CFAP61

5.30e-0518822870758b474457efa36488e0195f7357100f4b6a090
ToppCellrenal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

ERMP1 ADGRV1 MKLN1 NHS TRHDE PRUNE2 DIP2C

5.30e-051882287af740fa78542438fdff627ea1f74f4eee43316be
ToppCelldroplet-Kidney-KIDNEY-1m-Epithelial-Epcam____thick_ascending_tube_S_epithelial_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BCKDHB ERMP1 PAK6 ME3 GAL3ST1 SLC5A1 BCAM

5.30e-05188228714e120b20e76baa07b6510a94f0c2dcdfdd52357
ToppCellPosterior_cortex-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Pvalb-Inhibitory_Neuron.Gad1Gad2.Pvalb-Unc5b_(Neuron.Gad1Gad2.Pvalb-Unc5b)-|Posterior_cortex / BrainAtlas - Mouse McCarroll V32

VIT CFAP65 FLT3 PCDHA6 TLL1

5.31e-05792285cc17a013a4a57a99c404b10449ef61ce559631d1
ToppCellPosterior_cortex-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Pvalb-Inhibitory_Neuron.Gad1Gad2.Pvalb-Unc5b_(Neuron.Gad1Gad2.Pvalb-Unc5b)|Posterior_cortex / BrainAtlas - Mouse McCarroll V32

VIT CFAP65 FLT3 PCDHA6 TLL1

5.31e-0579228519fb2bc964589ea40e7b9f0809c641331c93dacd
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

ME3 BACE2 TRIM2 CLASP1 DYNC2H1 APBB2 LIMCH1

5.48e-051892287975c0f079903ae36b0ffa54e86294d42ec7697de
ToppCellRA-10._Endothelium_II|World / Chamber and Cluster_Paper

SPTBN1 ITGA9 PCDH15 ATP13A3 BACE2 GRB10 TLL1

5.48e-05189228775c248b9de5e2fb7a0baa8cdbab516e575cc4394
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

ME3 BACE2 TRIM2 CLASP1 DYNC2H1 APBB2 LIMCH1

5.48e-0518922877eb8f5a951e80f1cfac4d7c9eb169f4eb100c917
ToppCellRV-15._Ventricular_Cardiomyocyte_III|World / Chamber and Cluster_Paper

CMYA5 CPED1 MYPN PDLIM5 DIP2C AKAP13 CFAP61

5.48e-0518922870a82931b5f6c0a6427ca3edd5e2235ac49099d40
ToppCellAdult-Epithelial-alveolar_epithelial_cell_type_1-D231|Adult / Lineage, Cell type, age group and donor

SPTBN1 UNC13D APBB2 LMO7 DIP2C LIMCH1 BCAM

5.48e-0518922875a04cb25f8f0447b2cecdb6c3695029281aca26d
ToppCelldroplet-Kidney-KIDNEY-1m-Epithelial-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BCKDHB ERMP1 PAK6 ME3 GAL3ST1 SLC5A1 BCAM

5.48e-051892287443359d90fafae0c1de6bdcce9e8c95df6ea4de8
ToppCelldroplet-Limb_Muscle-nan-3m-Endothelial-unknown|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ERN1 KDM5C ZZEF1 FBXL21P CCDC117 CLASP1 KLHL36

5.48e-05189228716a4c92dd7a0d60f3691bd3130a091a9a54730f1
ToppCellRV-15._Ventricular_Cardiomyocyte_III|RV / Chamber and Cluster_Paper

CMYA5 CPED1 FAT1 MYPN PDLIM5 DIP2C AKAP13

5.66e-05190228793c3188dfeb0b2f9889f8ae9b9c1f2f34129c99b
ToppCellLV-06._Ventricular_Cardiomyocyte_II|World / Chamber and Cluster_Paper

CMYA5 PDLIM5 SLC5A1 LMO7 AKAP13 LIMCH1 CFAP61

5.66e-051902287de5ef606a002f85c2e0e3a36c1f259d0b85a76ff
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

PDGFRB ITGA7 CPED1 FNDC1 PDLIM5 MICAL2 EPB41L2

5.66e-05190228770c86dd454afb21d4a85db56c5f369d4b342bc97
ToppCellIPF-Epithelial-Club|World / Disease state, Lineage and Cell class

ITGA9 FAT1 TRIM2 ERN2 LMO7 LIMCH1 BCAM

5.85e-0519122873c88a6f1d74bb3b9173cd0ea3a63c6d9570e3954
ToppCellLPS_only-Stromal_mesenchymal-Lung_smooth_muscle|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PDGFRB ITGA7 CPED1 FNDC1 FAT1 PRUNE2 HHIP

5.85e-05191228708042952431ca1a6fd7dfc13f36eb28643979598
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

PDGFRB ITGA9 CPED1 FNDC1 PDLIM5 MICAL2 EPB41L2

5.85e-05191228739092a0aff8097617820c59f5fea9ee2bb4f63a2
ToppCellMesenchymal-vascular_smooth_muscle_cell|World / Lineage, Cell type, age group and donor

PDGFRB DGKH ITGA7 CPED1 FAT1 NHS NPAS4

5.85e-051912287fd89fbc62aa1c73e0f659991e3bd726a0c97bd68
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast-|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

PDGFRB ITGA9 CPED1 FNDC1 PDLIM5 MICAL2 EPB41L2

5.85e-051912287ee5f1b1c59029c46cbb1a00935c03b9317bb9da9
ToppCellControl-Stromal_mesenchymal|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

ITGA9 CPED1 FNDC1 PCDH15 TRHDE FKBP10 HHIP

5.85e-05191228714057205ddb9b4bbc582d1358d13cf36d979a61b
ToppCellwk_20-22-Mesenchymal-Myofibro_&_SMC-Vascular_SMC_2|wk_20-22 / Celltypes from embryonic and fetal-stage human lung

PDGFRB ITGA7 FAT1 NHS PDLIM5 BCAM NPAS4

6.05e-051922287a7d08416f07f29ad920168a3b52ddf992f263bf4
ToppCellIPF-Epithelial-Ciliated|IPF / Disease state, Lineage and Cell class

CFAP65 KIAA2012 TRIM2 DYNC2H1 DNAH2 DNAI4 CFAP61

6.05e-051922287354adc1354bf596fbc60dd45c0169688e6f45165
ToppCellLPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PDGFRB ITGA7 CPED1 FNDC1 FAT1 PRUNE2 HHIP

6.05e-051922287992d08092edbc68c47b945deb8708379738c239a
ToppCellControl-Epithelial-Club|Control / Disease state, Lineage and Cell class

ITGA9 FAT1 NHS TRIM2 LMO7 LIMCH1 BCAM

6.05e-051922287d84ed1ea4a03edaa18c804f75afb03bd7b1f0e16
ToppCellLV-04._Ventricular_Cardiomyocyte_I|LV / Chamber and Cluster_Paper

CMYA5 CPED1 MYPN ST7 PDLIM5 LMO7 LIMCH1

6.05e-051922287ad19e2c1d36a0566c9b12ced10db78f4781c8ea6
ToppCellEpithelial-club_cell|World / Lineage, Cell type, age group and donor

ADGRV1 FAT1 TRIM2 ERN2 PLEKHG4B LMO7 TLL1

6.25e-0519322872bdd09004fa433550958ec42ba4b06271a4aaf7c
ToppCell5'-Adult-SmallIntestine-Endothelial-lymphatic_endothelial-LEC3_(ADGRG3+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

SPTBN1 P4HA3 CMYA5 ITGA9 KCNF1 TLL1 EPB41L2

6.25e-051932287bd0027fa97de41ae22ff64a61c8e217496f122ca
ToppCellPBMC-Mild-Myeloid-cDC-cDC-cDC_0|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

MAN2B1 CPED1 FBP1 FLT3 CAPG MICAL2 CTNND1

6.25e-0519322876b3a2a32ec6dc96230cee4bbf03932f8a81e6683
ToppCellCOVID-19-Heart-CM_+_EC_+_Pericyte|Heart / Disease (COVID-19 only), tissue and cell type

CMYA5 CPED1 MYPN ATP13A3 PDLIM5 LMO7 CFAP61

6.25e-051932287dd5378a1ef8eb0eda9a3aae62f3c2f3a1402bda0
ToppCellPBMC-Mild-Myeloid-cDC-cDC-cDC_0|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

MAN2B1 CPED1 FBP1 FLT3 CAPG MICAL2 CTNND1

6.25e-051932287b18c61e360f5f094f260007a56b189e2a48369e4
ToppCellLPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

PDGFRB CPED1 PCDH15 NHS TRHDE AOX1 LIMCH1

6.25e-051932287fb28717fadd06c3840636d25409ce80c9254bd34
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Epithelial|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

CMYA5 FAT1 NHS TRHDE PRUNE2 LMO7 DIP2C

6.25e-0519322873866667dd221612589ae50f5c52f73a183a49ce6
ToppCellCOVID-19-Heart-CM_2|Heart / Disease (COVID-19 only), tissue and cell type

CMYA5 CPED1 MYPN PDLIM5 LMO7 AKAP13 CFAP61

6.67e-05195228775fc81bddb246dca3b437fb60827b1d4fe416405
ToppCellPBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Myeloid-Dendritic|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)

SCRN1 CPED1 FBP1 FLT3 CAPG LIMCH1 EPB41L2

6.67e-0519522874cbc36fb3ef9aef61367d3b37070a9a85fae1418
ToppCellrenal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

PDGFRB ITGA7 ITGA9 CPED1 PDLIM5 MICAL2 EPB41L2

6.89e-0519622871522958a92e0126326a9f0d9fb1c5b5c50b001ea
ToppCellrenal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

PDGFRB ITGA7 ITGA9 CPED1 PDLIM5 MICAL2 EPB41L2

6.89e-0519622871c8294014713684b50885e638668f2ce75f357f0
ToppCellBronchial-NucSeq|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations

ADGRV1 ATXN1 CLASP1 ST7 APBB2 DIP2C LIMCH1

6.89e-051962287ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

PDGFRB ITGA7 CPED1 FNDC1 PDLIM5 MICAL2 EPB41L2

6.89e-051962287fa445f4240c521cf04eb2e2f79a5c55fda31209a
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

PDGFRB ITGA7 CPED1 FNDC1 PDLIM5 MICAL2 EPB41L2

6.89e-051962287802f61e78a9a1030a86c4a980c398a73cd4d1574
ToppCell10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

SYNJ2 BACE2 CARNS1 PRUNE2 KIF13B HHIP CERCAM

7.11e-05197228782b8e22317cad6d3786bd70d91107007c0ccd7cd
ToppCellLPS_IL1RA-Epithelial_alveolar-AT_1-AT1|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

UNC13D FBP1 LMO7 CERCAM LIMCH1 BCAM DSEL

7.34e-0519822875a85c286f79cde5811d2595a3397c6fb7685adee
ToppCell10x_3'_v2v3-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-G|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

SYNJ2 CARNS1 TRIM2 GAL3ST1 HHIP CERCAM LIMCH1

7.34e-051982287bdabdb11217ea16e5863aa6bfb0f04d48b17f81e
DrugL(-)-vesamicol hydrochloride [112709-59-8]; Down 200; 13.6uM; MCF7; HT_HG-U133A

CDK20 LYRM9 SPTBN1 SYNJ2 ETAA1 PHLPP1 TBCD APC ZNF263 KLHL36 AKAP13 CABIN1 EPB41L2

7.20e-08198220135475_DN
DrugCinoxacin [28657-80-9]; Down 200; 15.2uM; MCF7; HT_HG-U133A

DOHH HPS1 ETAA1 TBCD TRIM2 APBB2 MACROH2A1 ERN2 PDLIM5 BCAM TOPORS PPP6R2

5.19e-07197220126257_DN
DrugDubinidine [22964-77-8]; Down 200; 14.6uM; MCF7; HT_HG-U133A

LYRM9 DIP2A KCNF1 HPS1 PHLPP1 TRIM2 DYNC2H1 CAPG APBB2 GRB10 ENPP4 LIMCH1

5.47e-07198220123554_DN
DrugICI182,780; Up 200; 1uM; PC3; HT_HG-U133A

CUL9 BCKDHB ETAA1 USP7 FKBP10 ST7 APBB2 ENPP4 BCAM PPP6R2 ARHGAP45

3.63e-06197220117495_UP
DrugGalanthamine hydrobromide [1953-04-4]; Up 200; 10.8uM; PC3; HT_HG-U133A

LYRM9 DOHH ERN1 PAK6 ZZEF1 ME3 AGO4 HPS1 APC PDLIM5 LIMCH1

3.63e-06197220114186_UP
DrugBumetanide [28395-03-1]; Down 200; 11uM; MCF7; HT_HG-U133A

TNRC6B AXIN1 FLOT2 ST7 APC GRB10 ERN2 KLHL36 AKAP13 CABIN1 PPP6R2

3.63e-06197220117440_DN
Drug5-aza-2′-deoxycytidine; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

DOHH SAMD9 DIP2A ATXN1 ETAA1 MACROH2A2 SLC12A6 FKBP10 DYNC2H1 CEP63 CABIN1

4.00e-0619922011920_DN
DrugMolindone hydrochloride [15622-65-8]; Down 200; 12.8uM; MCF7; HT_HG-U133A

DOHH KDM5C KCNF1 TBCD FKBP10 TRIM2 CLASP1 CAPG AOX1 CEP63 CABIN1

4.00e-06199220117337_DN
DrugNitrofural [59-87-0]; Down 200; 20.2uM; MCF7; HT_HG-U133A

DOHH HPS1 FKBP10 ANKFY1 TRIM2 DYNC2H1 GRB10 ERN2 CEP164 PDLIM5

2.12e-05195220103320_DN
DrugSulindac [38194-50-2]; Up 200; 11.2uM; PC3; HT_HG-U133A

CUL9 STAT2 AXIN1 ETAA1 ATP13A3 TBCD CUL4A KIF13B TRIM2 ST7

2.12e-05195220101815_UP
DrugRicinine [524-40-3]; Down 200; 24.4uM; MCF7; HT_HG-U133A

CUL9 KCNF1 PHLPP1 KMT2A FKBP10 TRIM2 GRB10 ERN2 CEP164 PPP6R2

2.12e-05195220106067_DN
DrugTetrahydroalstonine [6474-90-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A

LYRM9 SPTBN1 KCNF1 MTMR3 TRIM2 APC PCDHA6 ERN2 AKAP13 LIMCH1

2.12e-05195220102748_DN
DrugLevodopa [59-92-7]; Down 200; 20.2uM; PC3; HT_HG-U133A

LYRM9 UNC45A AGO4 ANKFY1 TRIM2 APBB2 PDLIM5 TRIM23 KLHL36 CA5B

2.21e-05196220104571_DN
DrugSpectinomycin dihydrochloride [21736-83-4]; Down 200; 9.8uM; MCF7; HT_HG-U133A

TNRC6B CUL9 HPS1 MTMR3 ZSCAN2 SLC12A6 APBB2 ERN2 PDLIM5 PPP6R2

2.21e-05196220103327_DN
DrugEpivincamine [6835-99-0]; Down 200; 11.2uM; MCF7; HT_HG-U133A

CUL9 BCKDHB KMT2A ANKFY1 AOX1 PCDHA6 ENPP4 AKAP13 LIMCH1 BCAM

2.21e-05196220102775_DN
DrugBetazole hydrochloride; Down 200; 27uM; PC3; HT_HG-U133A

KDM5C TNRC6B ZNF202 SEC23A ST7 APBB2 ENPP4 ERN2 CEP164 TOPORS

2.21e-05196220106344_DN
DrugHecogenin [467-55-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A

MAN2B1 SPTBN1 TNRC6B MTMR3 ETAA1 FKBP10 ANKFY1 TRIM2 KLHL36 PPP6R2

2.21e-05196220107175_DN
DrugViomycin sulfate [37883-00-4]; Down 200; 5.2uM; PC3; HT_HG-U133A

CUL9 TTF1 AXIN1 SUPT6H USP7 TRIM23 KLHL36 BCAM ARHGAP45 DDX28

2.21e-05196220107278_DN
DrugHydrochlorothiazide [58-93-5]; Up 200; 13.4uM; MCF7; HT_HG-U133A

ERCC6 ZZEF1 SPTBN5 AGO4 ETAA1 FKBP10 DYNC2H1 ENPP4 CABIN1 DDX28

2.21e-05196220104970_UP
DrugGuanabenz acetate [23256-50-0]; Up 200; 13.8uM; PC3; HG-U133A

TBRG4 TNRC6B UNC45A MTMR3 MKLN1 MACROH2A2 ENPP4 ZNF106 NUP93 GPN3

2.21e-05196220101961_UP
Drugfenarimol

CYP8B1 MTSS1 CMYA5 TRAT1 HPS1 GRB10

2.23e-05592206CID000043226
DrugPilocarpine nitrate [148-72-1]; Down 200; 14.8uM; MCF7; HT_HG-U133A

CDK20 DOHH KDM5C SPTBN1 CUL9 BCKDHB SYNJ2 ETAA1 TRIM23 AKAP13

2.31e-05197220105341_DN
DrugTalampicillin hydrochloride [39878-70-1]; Up 200; 7.8uM; MCF7; HT_HG-U133A

LYRM9 DOHH ERCC6 AXIN1 KCNF1 TBCD ST7 DCHS1 AKAP13 CABIN1

2.31e-05197220107014_UP
DrugMeglumine [6284-40-8]; Up 200; 20.4uM; MCF7; HT_HG-U133A

CUL9 BCKDHB SYNJ2 SUPT6H CUL4A FKBP10 FLOT2 TRIM2 ENPP4 LIMCH1

2.31e-05197220105285_UP
DrugFlupentixol dihydrochloride cis-(Z) [2413-38-9]; Down 200; 7.8uM; MCF7; HT_HG-U133A

DOHH SPTBN1 TNRC6B BCKDHB SYNJ2 KMT2A FKBP10 ERN2 CEP164 DDX28

2.31e-05197220102643_DN
DrugSR-95639A [115767-94-7]; Up 200; 10uM; MCF7; HT_HG-U133A

ERCC6 CPED1 SYNJ2 SUPT6H DYNC2H1 APC CEP164 AKAP13 CABIN1 DDX28

2.41e-05198220104977_UP
DrugProcaine hydrochloride [51-05-8]; Down 200; 14.6uM; PC3; HT_HG-U133A

TBRG4 KDM5C FEM1C DIP2A SUPT6H MKLN1 CLASP1 ST7 CABIN1 EPB41L2

2.41e-05198220106329_DN
DrugApramycin [37321-09-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A

TNRC6B ZNF202 ZZEF1 KIF13B FKBP10 ANKFY1 AOX1 APC AKAP13 CABIN1

2.41e-05198220107334_DN
Drugchlorpromazine hydrochloride; Down 200; 1uM; MCF7; HG-U133A

UNC45A ZZEF1 KMT2A CAPG APC ERN2 PDLIM5 DENND4C SLC5A1 EPB41L2

2.41e-0519822010426_DN
DrugAmprolium hydrochloride [137-88-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A

ATXN1 SYNJ2 FLOT2 TRIM2 CAPG AOX1 PDLIM5 BEX4 BCAM EPB41L2

2.41e-05198220101479_DN
DrugLobeline alpha (-) hydrochoride [134-63-4]; Down 200; 10.6uM; MCF7; HT_HG-U133A

LYRM9 DOHH KDM5C HPS1 PHLPP1 TRIM2 GRB10 ERN2 BCAM ARHGAP45

2.52e-05199220106258_DN
DrugLetrozole [112809-51-5]; Down 200; 14uM; MCF7; HT_HG-U133A

DOHH AXIN1 ETAA1 USP7 FKBP10 CAPG AOX1 APC ERN2 AKAP13

2.63e-05200220107336_DN
DrugAC1L1GT5

MAN2B1 AXIN1 TRAT1 KIF13B DSG1 GAL3ST1 APC

3.84e-05952207CID000003829
Drugdeoxyhypusine

DOHH MAN2B1 SPTBN1 P4HA3

5.41e-05222204CID000122083
Drug2-propylpentanoic acid; Up 200; 200uM; MCF7; HT_HG-U133A_EA

LYRM9 SAMD9 MTSS1 ZNF202 MTMR3 KMT2A SLC12A6 GRB10 LIMCH1

1.05e-041912209994_UP
DrugPHA-00851261E [724719-49-7]; Down 200; 10uM; PC3; HT_HG-U133A

UNC45A AXIN1 SYNJ2 SUPT6H FLOT2 CEP164 BCAM CABIN1 PPP6R2

1.09e-0419222094330_DN
DrugAspartic acid, N-acetyl (R,S) [997-55-7]; Up 200; 22.8uM; MCF7; HT_HG-U133A

SPTA1 GFAP SASH3 ZSCAN2 LMO7 MICAL2 LIMCH1 DDX28 PHLPP2

1.14e-0419322094125_UP
DrugHymecromone [90-33-5]; Down 200; 22.8uM; PC3; HT_HG-U133A

KDM5C SYNJ2 ZSCAN2 ATP13A3 SEC23A ANKFY1 APC MARCHF7 ERN2

1.14e-0419322094623_DN
DrugAcemetacin [53164-05-9]; Up 200; 9.6uM; MCF7; HT_HG-U133A

AXIN1 SYNJ2 KIF13B DYNC2H1 ERN2 TRIM23 AKAP13 PPP6R2 ARHGAP45

1.18e-0419422097442_UP
DrugChlorpropamide [94-20-2]; Down 200; 14.4uM; MCF7; HT_HG-U133A

BCKDHB HPS1 ATP13A3 SEC23A FLOT2 ANKFY1 AOX1 TRIM23 BEX4

1.23e-0419522093210_DN
DrugTriflusal [322-79-2]; Down 200; 16.2uM; MCF7; HT_HG-U133A

SPTBN1 ZZEF1 DIP2A SUPT6H ETAA1 ZSCAN2 APBB2 APC PDLIM5

1.23e-0419522092867_DN
DrugDyclonine hydrochloride [536-43-6]; Up 200; 12.2uM; MCF7; HT_HG-U133A

CDK20 SPTBN1 ZNF202 SUPT6H GRB10 ENPP4 CEP164 TRIM23 ARHGAP45

1.28e-0419622097423_UP
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

ERCC6 KDM5C UNC45A STAT2 ETAA1 APC ERN2 AKAP13 BCAM

1.28e-0419622093872_DN
DrugAllantoin [97-59-6]; Down 200; 25.2uM; MCF7; HT_HG-U133A

CUL9 BCOR ZZEF1 SUPT6H HPS1 ETAA1 ST7 GRB10 KLHL36

1.28e-0419622091678_DN
DrugEthoxyquin [91-53-2]; Up 200; 18.4uM; PC3; HT_HG-U133A

PDGFRB ITGA7 KMT2A CUL4A PRUNE2 DCHS1 CA5B EPB41L2 PHLPP2

1.28e-0419622094321_UP
DrugIodipamide [606-17-7]; Up 200; 3.6uM; MCF7; HT_HG-U133A

SAMD9 SPTBN1 BCKDHB GFAP SPTBN5 FKBP10 APBB2 CEP164 CABIN1

1.28e-0419622096490_UP
DrugRetinoic acid [302-79-4]; Down 200; 13.4uM; PC3; HT_HG-U133A

SPTBN1 CUL9 STAT2 AXIN1 ATXN1 FKBP10 CABIN1 ARHGAP45 DDX28

1.28e-0419622095767_DN
Drug(R)-(+)-Atenolol [56715-13-0]; Down 200; 15uM; HL60; HT_HG-U133A

TNFSF14 MTSS1 UNC45A FBP1 SYNJ2 DYNC2H1 ERN2 PDLIM5 TRIM23

1.28e-0419622092496_DN
Drugfluphenazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A

SPTBN1 BCKDHB AXIN1 PHLPP1 TBCD ANKFY1 DYNC2H1 MARCHF7 DDX28

1.28e-0419622091662_DN
DrugTriprolidine hydrochloride [550-70-9]; Up 200; 12.8uM; MCF7; HT_HG-U133A

SPTBN1 CUL9 HPS1 ATP13A3 APBB2 GRB10 TRIM23 DNAI4 ARHGAP45

1.28e-0419622097408_UP
DrugAjmaline [4360-12-7]; Up 200; 12.2uM; MCF7; HT_HG-U133A

SYNJ2 MTMR3 MKLN1 KMT2A FKBP10 APC GRB10 PDLIM5 AKAP13

1.33e-0419722097484_UP
DrugDesipramine hydrochloride [58-28-6]; Down 200; 13.2uM; MCF7; HT_HG-U133A

DOHH UNC45A FEM1C AXIN1 SYNJ2 KMT2A APC CEP63 CTNND1

1.33e-0419722095292_DN
Drug2-propylpentanoic acid; Down 200; 200uM; MCF7; HT_HG-U133A

KDM5C SPTBN1 CUL9 SUPT6H HPS1 TBCD KIF13B ST7 PPP6R2

1.33e-0419722095211_DN
Drugpioglitazone HCl; Up 200; 10uM; MCF7; HT_HG-U133A

LYRM9 ERN1 MTSS1 ETAA1 FKBP10 GRB10 PDLIM5 LIMCH1 CA5B

1.33e-0419722095972_UP
DrugGuanabenz acetate [23256-50-0]; Up 200; 13.8uM; MCF7; HT_HG-U133A

KDM5C MATN1 BCKDHB PRUNE2 GRB10 CEP164 BCAM CA5B DDX28

1.33e-0419722095703_UP
DrugLevonordefrin [829-74-3]; Down 200; 21.8uM; MCF7; HT_HG-U133A

AXIN1 ATP13A3 TBCD CAPG GRB10 TOPORS CABIN1 PPP6R2 EPB41L2

1.33e-0419722097208_DN
DrugMimosine [500-44-7]; Up 200; 20.2uM; PC3; HT_HG-U133A

ITGA7 HPS1 KMT2A PRUNE2 APBB2 APC CCDC7 MICAL2 DNAI4

1.33e-0419722096703_UP
DrugMebendazole [31431-39-7]; Down 200; 13.6uM; MCF7; HT_HG-U133A

BCKDHB SUPT6H HPS1 DYNC2H1 APBB2 PCDHA6 ENPP4 TRIM23 EPB41L2

1.33e-0419722092300_DN
DrugSaquinavir mesylate [149845-06-7]; Down 200; 5.2uM; PC3; HT_HG-U133A

SPTBN1 TNRC6B STAT2 AXIN1 SYNJ2 FKBP10 FLOT2 ANKFY1 BCAM

1.33e-0419722095770_DN
DrugPridinol methanesulfonate salt [6856-31-1]; Down 200; 10.2uM; MCF7; HT_HG-U133A

SPTBN1 SUPT6H ETAA1 KMT2A KIF13B CAPG APBB2 GRB10 PPP6R2

1.33e-0419722093456_DN
DrugTridihexethyl chloride; Down 200; 11.4uM; MCF7; HT_HG-U133A

LYRM9 KDM5C HPS1 PHLPP1 TBCD ERN2 MICAL2 BCAM CABIN1

1.38e-0419822095486_DN
DrugCefmetazole sodium salt [56796-39-5]; Up 200; 8.2uM; PC3; HT_HG-U133A

DOHH KDM5C ITGA7 SPTBN5 CEACAM21 KCNF1 ZSCAN2 ANKFY1 PDLIM5

1.38e-0419822095868_UP
DrugDiazoxide [364-98-7]; Down 200; 17.4uM; MCF7; HT_HG-U133A

KDM5C AXIN1 KCNF1 APBB2 MACROH2A1 PDLIM5 TRIM23 MICAL2 BEX4

1.38e-0419822097168_DN
DrugNoscapine [128-62-1]; Down 200; 9.6uM; MCF7; HT_HG-U133A

MAN2B1 BCKDHB SUPT6H HPS1 DYNC2H1 AOX1 APBB2 GRB10 MICAL2

1.38e-0419822097204_DN
DrugMegestrol acetate [595-33-5]; Down 200; 10.4uM; MCF7; HT_HG-U133A

CUL9 ZNF202 SYNJ2 KCNF1 HPS1 KIF13B CAPG LIMCH1 CABIN1

1.38e-0419822095013_DN
DrugQuinic acid [86-68-0]; Up 200; 19.6uM; PC3; HT_HG-U133A

LYRM9 PAK6 AGO4 SYNJ2 KCNF1 APC PDLIM5 LMO7 CABIN1

1.38e-0419822097317_UP
DrugPinacidil [85371-64-8]; Up 200; 16.4uM; MCF7; HT_HG-U133A

MAN2B1 BCKDHB KCNF1 HPS1 USP7 DYNC2H1 APBB2 TRIM23 MICAL2

1.38e-0419822097437_UP
DrugEtanidazole [22668-01-5]; Down 200; 18.6uM; MCF7; HT_HG-U133A

SYNJ2 HPS1 CUL4A CAPG MACROH2A1 ERN2 TRIM23 CABIN1 ARHGAP45

1.38e-0419822096211_DN
DrugDicumarol [66-76-2]; Up 200; 11.8uM; PC3; HT_HG-U133A

CDK20 PAK6 KMT2A FKBP10 APC DHX30 AVIL BCAM CABIN1

1.38e-0419822094323_UP
Drug5194442; Down 200; 20uM; MCF7; HT_HG-U133A

PDGFRB ZNF202 SYNJ2 FKBP10 TRIM2 AOX1 ERN2 LIMCH1 EPB41L2

1.38e-0419822096599_DN
Drug9-deoxy-9-methylene-16,16-dimethyl Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A

BCKDHB ITGA7 SEC23A APBB2 APC CEP164 PDLIM5 LIMCH1 PPP6R2

1.38e-0419822097557_DN
DrugHippeastrine hydrobromide [22352-41-6]; Up 200; 10uM; PC3; HT_HG-U133A

DOHH STAT2 AXIN1 KCNF1 TBCD TRIM2 APC DNAI4 CABIN1

1.38e-0419822097381_UP
DrugNifurtimox [23256-30-6]; Down 200; 14uM; PC3; HT_HG-U133A

LYRM9 DOHH STAT2 ME3 SYNJ2 KMT2A ANKFY1 PDLIM5 CABIN1

1.38e-0419822096608_DN
Drugcarbamazepine; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

DOHH SAMD9 SYNJ2 ETAA1 TBCD CAPG CEP63 PPP6R2 ARHGAP45

1.38e-041982209919_DN
DrugSC 19220; Up 200; 10uM; PC3; HT_HG-U133A

TBRG4 TNRC6B CUL9 TRIM2 DYNC2H1 MARCHF7 CEP164 DIP2C PPP6R2

1.38e-0419822097095_UP
Drugnordihydroguaiaretic acid; Down 200; 1uM; MCF7; HT_HG-U133A

CEP76 DIP2A PHLPP1 SEC23A GRB10 ERN2 AKAP13 CABIN1 TP53BP2

1.44e-0419922096942_DN
DrugXamoterol hemifumarate [73210-73-8]; Down 200; 5uM; MCF7; HT_HG-U133A

CDK20 SPTBN1 CUL9 AXIN1 USP7 CAPG GRB10 LIMCH1 CABIN1

1.44e-0419922095363_DN
DrugIsopyrin hydrochloride [18342-39-7]; Up 200; 14.2uM; PC3; HT_HG-U133A

SPTBN1 TTF1 ME3 SUPT6H TBCD TRIM2 APC ERN2 BEX4

1.44e-0419922095879_UP
DrugGibberellic acid [77-06-5]; Down 200; 11.6uM; MCF7; HT_HG-U133A

AXIN1 ETAA1 USP7 MACROH2A2 FKBP10 DYNC2H1 AOX1 GRB10 CABIN1

1.44e-0419922097330_DN
Drug(+/-)-blebbistatin; Down 200; 17uM; MCF7; HT_HG-U133A_EA

GLT8D1 KDM5C TNRC6B BCKDHB DIP2A KMT2A AOX1 BEX4 PPP6R2

1.44e-041992209954_DN
DrugTalampicillin hydrochloride [39878-70-1]; Down 200; 7.8uM; PC3; HT_HG-U133A

KDM5C SPTBN1 TNRC6B AXIN1 KIF13B ANKFY1 GRB10 MARCHF7 DIP2C

1.44e-0419922097254_DN
DrugOxymetazoline hydrochloride [2315-02-8]; Down 200; 13.4uM; PC3; HT_HG-U133A

DOHH KDM5C SPTBN1 MTSS1 TTF1 SEC23A SLC12A6 KIF13B PPP6R2

1.44e-0419922096350_DN
Drug2-propylpentanoic acid; Up 200; 50uM; MCF7; HT_HG-U133A

UNC45A SYNJ2 HPS1 FKBP10 AOX1 GRB10 PDLIM5 MICAL2 EPB41L2

1.44e-0419922096941_UP
Drugtetraethylenepentamine pentahydrochloride; Up 200; 100uM; MCF7; HG-U133A

SPTBN1 MTMR3 KMT2A MACROH2A2 CARD14 APBB2 GRB10 ERN2 TRIM23

1.44e-041992209406_UP
Drugestradiol, USP; Down 200; 0.01uM; PC3; HG-U133A

AXIN1 SUPT6H KMT2A CARD14 PRUNE2 DYNC2H1 APBB2 TG LIMCH1

1.49e-042002209665_DN
Drugdihydrolipoamide

BCKDHB GFAP ATXN1 SUPT6H DHTKD1 TG CTNND1

1.60e-041192207CID000000663
Drugbenz(a)anthracene

GLT8D1 PDGFRB SPTBN1 ZSCAN26 LCA5L CUL9 ITGA7 STAT2 DDX5 CFAP65 FNDC1 AGO4 CEP95 HPS1 PHLPP1 ATP13A3 CAPS2 TRIM2 PCDHGA9 DNAH2 GRB10 PDLIM5 SLC5A1 IGHM AKAP13 ARHGAP45

1.99e-04125122026ctd:C030935
DrugADPribulose

SPTA1 SPTBN1 SPTBN5

2.37e-04132203CID000197570
Diseaseprimary ovarian insufficiency (implicated_via_orthology)

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 MOV10L1 USP17L3 USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

9.78e-254622817DOID:5426 (implicated_via_orthology)
Diseasecongenital heart disease (implicated_via_orthology)

USP17L7 USP17L21 USP17L1 USP17L20 USP17L19 USP17L18 USP17L17 USP17L3 KMT2A USP17L13 USP17L12 USP17L11 USP17L24 USP17L5 USP17L10 USP17L22 USP17L15

2.85e-216922817DOID:1682 (implicated_via_orthology)
Diseasecesarean section, anxiety

ATXN1 MAT2B DIP2C

2.48e-0582283EFO_0005230, EFO_0009636
Disease1-ribosyl-imidazoleacetate measurement

CARNS1 DHTKD1 TIGD5

3.70e-0592283EFO_0800034
Diseasemean platelet volume

SPTA1 SPTBN1 UNC13D BCOR EXOC3L4 USP7 ATP13A3 TBCD HOMEZ CCDC117 CUL4A SLC12A6 PCDHGA9 PCDHGA5 STXBP5 NPEPPS MACROH2A1 PDLIM5 TRIM40 ARHGAP45 PCDHGA8

4.81e-05102022821EFO_0004584
Diseasemean reticulocyte volume

SAMD9 SPTA1 CPED1 ME3 DIP2A PTPRN CARNS1 CUL4A FLOT2 FLT3 CLASP1 PCDHGA5 NPEPPS DNAH2 GRB10 ENPP4 AKAP13 EPB41L2

5.48e-0579922818EFO_0010701
DiseaseMixed phenotype acute leukemia

KMT2A FLT3

5.94e-0522282C2826025
Diseaseopen-angle glaucoma

ME3 GNL2 KMT2A NUDT7 PCDHGA5 NPEPPS APBB2 LMO7

1.27e-041912288EFO_0004190
Diseaseintraocular pressure measurement

SPTBN1 ME3 SYNJ2 GNL2 KMT2A DYNC2H1 PCDHGA5 ST7 ZNF106 LMO7 TLL1 AKAP13 DSEL

1.82e-0450922813EFO_0004695
Diseasepulse pressure measurement

BRPF3 GLT8D1 LCA5L TNRC6B UNC13D ITGA9 DDX5 DIP2A FNDC1 ATXN1 SUPT6H MYPN MKLN1 HOMEZ FLOT2 DYNC2H1 PCDHA6 PCDHA4 CEP164 PDLIM5 DENND4C CERCAM AKAP13 CTNND1

2.14e-04139222824EFO_0005763
Diseaseage-related macular degeneration, cataract, glaucoma

ME3 PCDHGA5

3.53e-0442282EFO_0001365, MONDO_0005041, MONDO_0005129
DiseaseAcute myelomonocytic leukemia

KMT2A FLT3

5.85e-0452282C0023479
Diseaseatopy

ADGRV1 PAK6

5.85e-0452282EFO_0002686
DiseaseSmall cell carcinoma of lung

LYRM9 PAK6 KMT2A DIP2C

8.11e-04542284C0149925
Diseaseresponse to antineoplastic agent, response to doxorubicin

ME3 PCDHGA5

8.74e-0462282GO_0097327, GO_1902520
DiseaseHepatoblastoma

AXIN1 APC

8.74e-0462282C0206624
DiseasePleocytosis

FLT3 APC

8.74e-0462282C0151857
DiseaseLeukocytosis

FLT3 APC

8.74e-0462282C0023518
Diseasemental development measurement

PCDHGA9 PCDHGA5 PCDHGA8

9.24e-04252283EFO_0008230
Diseasecorpus callosum mid-anterior volume measurement

GAL3ST1 GRB10 TG

1.16e-03272283EFO_0010297
Diseasecerebral white matter volume change measurement, age at assessment

VIT KMT2A NPEPPS

1.29e-03282283EFO_0008007, EFO_0021499
Diseaseintelligence, response to cranial radiation therapy

DCHS2 TRIM2 NUP93

1.29e-03282283EFO_0004337, EFO_0010950
DiseaseAcute erythroleukemia - M6a subtype

KMT2A FLT3

1.61e-0382282C2930975
DiseaseAcute myeloid leukemia FAB-M6

KMT2A FLT3

1.61e-0382282C2930976
DiseaseAcute erythroleukemia - M6b subtype

KMT2A FLT3

1.61e-0382282C2930977
DiseaseAcute erythroleukemia

KMT2A FLT3

1.61e-0382282C2930974
DiseaseCiliopathies

ADGRV1 PCDH15 DYNC2H1 CEP164 TOPORS

1.67e-031102285C4277690
DiseasePR interval

SPTBN1 CUL9 ITGA9 FAT1 CEP95 MKLN1 KIF13B PCDHA4 PDLIM5 CCDC7 MICAL2

1.74e-0349522811EFO_0004462
DiseaseSevere Congenital Microcephaly

ERCC6 TBCD CEP63

1.74e-03312283C3853041
DiseaseHEPATOCELLULAR CARCINOMA

AXIN1 APC

2.06e-0392282114550
DiseaseHepatocellular carcinoma

AXIN1 APC

2.06e-0392282cv:C2239176
DiseaseMicrolissencephaly

ERCC6 TBCD CEP63

2.09e-03332283C1956147
Diseaseprostate cancer (implicated_via_orthology)

PDGFRB P4HA3 APC

2.09e-03332283DOID:10283 (implicated_via_orthology)
Diseasechildhood trauma measurement, alcohol consumption measurement

PCDHGA9 PCDHGA5 MARCHF7 PCDHGA8

2.25e-03712284EFO_0007878, EFO_0007979
Diseaseresponse to escitalopram, response to citalopram

ZNF202 APBB2

2.57e-03102282EFO_0006329, EFO_0007871
Diseaseage of onset of depressive disorder, wellbeing measurement

CMYA5 ARHGAP45

2.57e-03102282EFO_0007869, OBA_2040166
Diseasechemotherapy-induced alopecia, response to antimicrotubule agent

ME3 PCDHGA5

3.12e-03112282EFO_0005260, EFO_0005400
DiseaseTrigeminal Neuralgia

GFAP PRKCG

3.73e-03122282C0040997
DiseaseSecondary Trigeminal Neuralgia

GFAP PRKCG

3.73e-03122282C0393787
DiseaseTrigeminal Neuralgia, Idiopathic

GFAP PRKCG

3.73e-03122282C0393786
Diseaseacute myeloid leukemia (implicated_via_orthology)

KMT2A FLT3

3.73e-03122282DOID:9119 (implicated_via_orthology)
Diseasevolumetric bone mineral density

SPTBN1 ADGRV1 AXIN1

4.19e-03422283EFO_0007620
Diseaseaortic stenosis, aortic valve calcification

ME3 PCDHGA5 DENND4C

4.19e-03422283EFO_0000266, EFO_0005239
Diseasevelocity of sound measurement

SPTBN1 CPED1

4.38e-03132282EFO_0005654
DiseaseCongenital pontocerebellar hypoplasia

RARS2 TOE1

4.38e-03132282C0266468
Diseasemacrophage migration inhibitory factor measurement

USP7 MAT2B TIGD5

4.47e-03432283EFO_0008221
DiseaseUterine leiomyoma

TNRC6B CCDC117 DNAH2 PDLIM5

5.49e-03912284HP_0000131
Diseasepsoriasis

SCRN1 PAK6 STAT2 MYPN CARD14 FLT3 AKAP13

5.52e-032732287EFO_0000676
Diseaselymphocyte percentage of leukocytes

ERN1 CYP8B1 SPTA1 STAT2 ATXN1 FLT3 STXBP5 PCDHA6 MACROH2A1 DNAI4 CFAP61 ARHGAP45

5.86e-0366522812EFO_0007993
DiseaseNeurodevelopmental Disorders

KATNAL2 TNRC6B KMT2A DHX30

5.93e-03932284C1535926
Diseaseplatelet component distribution width

SPTA1 MTSS1 ZZEF1 SYNJ2 EXOC3L4 MOV10L1 USP7 ATP13A3 CUL4A PRUNE2 NPEPPS ENPP4 AKAP13

6.16e-0375522813EFO_0007984

Protein segments in the cluster

PeptideGeneStartEntry
HPVSQEVLQATDIDR

TRHDE

506

Q9UKU6
DQDAIDVIIHVARNP

TRHDE

916

Q9UKU6
VQEAPRLEPANEEHN

TTF1

451

Q15361
VARPRAQETLQEVHR

EXOC3L4

561

Q17RC7
RDPEVVNDESSLVRH

BACE2

501

Q9Y5Z0
EEVEADRNVNHLPSL

CCDC117

161

Q8IWD4
PVEVDHDQLEQFRTL

CA5B

251

Q9Y2D0
SDLAEVVRHAQRPLA

CDK20

86

Q8IZL9
TEADISQHLTNREVP

CFAP61

781

Q8NHU2
EVATRPLVQDLLNHD

AVIL

266

O75366
ALHRIQNLAPSDEES

APBB2

246

Q92870
HLSRAVISDPEQNLA

CAPS2

236

Q9BXY5
LSTHNEVPNERLVVE

CCDC7

706

Q96M83
EVPNERLVVEHQESL

CCDC7

711

Q96M83
SREQLNETTVLAPHE

CPED1

246

A4D0V7
IPNRHIEHNEARDDV

BEX4

66

Q9NWD9
AVCLIENPTEENRHR

ATP13A3

111

Q9H7F0
EQALPVASEEEQQRH

ANKRD20A4P

361

Q4UJ75
NHVLTIDPIRQEDAG

CEACAM21

196

Q3KPI0
EERIEELIHTINGNP

DEPDC4

201

Q8N2C3
IAPRHILLAVANDEE

MACROH2A2

76

Q9P0M6
ELIATVRRPAEAEAH

FLOT2

281

Q14254
VTPRHILLAVANDEE

MACROH2A1

76

O75367
AEPRRENISHNTQDI

AKAP13

1101

Q12802
DHKEQPIVTENAERQ

ADGRV1

4806

Q8WXG9
PLESEADVERAVHQV

CARNS1

531

A5YM72
DVDNILIPENRAHLS

BRPF3

726

Q9ULD4
IREELAPDQQHLSTE

CEP76

36

Q8TAP6
ILHIPSEERDNAIRV

DCP2

21

Q8IU60
DDSVQALDVITRHLP

AGO4

146

Q9HCK5
QQESPEASSLHILER

ANKRD24

351

Q8TF21
QSVVPASEHRRLQEE

ANKRD24

911

Q8TF21
PAADLEVQQATHREA

ATXN1

391

P54253
HVNGDSPEEVVRATR

DHTKD1

396

Q96HY7
VDPHRDTILNAIEQH

DHX30

436

Q7L2E3
REENPLNHNVVDAST

BCOR

46

Q6W2J9
AALQAHADDPERVVR

DOHH

256

Q9BU89
IPEINDSIRAHCEEN

ERMP1

726

Q7Z2K6
DRHQIQAVEPSAQAL

ERCC6

76

Q03468
VSSVQENHENERIPR

TP53BP2

681

Q13625
ENDPTHIQLREEVST

ASZ1

431

Q8WWH4
ISPDRIEELSVVNHA

AOX1

286

Q06278
EGISELPHVERNLQE

NUP93

21

Q8N1F7
HPEVSRDHIINALQE

RBM44

1006

Q6ZP01
THIRVTVLDANDNAP

PCDHGA5

226

Q9Y5G8
VRIHVTVLDTNDNAP

PCDHGA8

226

Q9Y5G5
VLASDVIHAQSRDLP

CDC42BPG

1011

Q6DT37
ERLLAESPNHVVAEA

P4HA3

271

Q7Z4N8
VFHVDVEVRDINDNP

PCDHA6

116

Q9UN73
QTLLHRAIDENNEPT

ANKFY1

726

Q9P2R3
DRHQIQAVEPSAQAL

ERCC6

76

P0DP91
LHPAATVEDAAQRRQ

BCKDHB

36

P21953
RVTDEILHLVPNIDN

PAPOLB

206

Q9NRJ5
VNVRDSDDNSPLHIA

FEM1C

521

Q96JP0
ARIVVNVSDTNDHAP

FAT1

1546

Q14517
PLDREQRAEHVLTVV

DCHS1

1606

Q96JQ0
QREEAAAVLPQTAHS

PTPRN

556

Q16849
IDIAATLEHVRDQRP

PTPRN

936

Q16849
RDPQERATAQELLDH

PAK6

641

Q9NQU5
VADEQRVPAHRNLLA

KLHL36

51

Q8N4N3
QPEREAHARQVLENI

KLHL36

221

Q8N4N3
NPEEQRSSILHLQEA

KIAA0100

1806

Q14667
AQREEEQEHSNKAPR

GNL2

661

Q13823
ASHVRQLQRDQEPDV

ARHGAP45

541

Q92619
EEIPRAALNTVHEAN

LIMS3

16

P0CW19
EEIPRAALNTVHEAN

LIMS4

16

P0CW20
ATLRQIASEPQDEHV

MATN1

186

P21941
IEAVLQVHFALPDSR

MOV10L1

781

Q9BXT6
VHCAAERRPDVVENQ

MAT2B

91

Q9NZL9
EAVDNHPLALQLDRT

CFAP65

1036

Q6ZU64
EVQLLQESDRHPNVL

ERN2

561

Q76MJ5
LQAQQHLPRADDVEV

KIAA1614

671

Q5VZ46
QLISLDQVHIPEAVR

BNIPL

331

Q7Z465
DQVHIPEAVRQLDRD

BNIPL

336

Q7Z465
EHPDLARRTAQEVET

DDX5

61

P17844
ALAQAIREAREQHPD

EPB41L2

971

O43491
QNSDLQIRPVDTTHD

CD200R1L

106

Q6Q8B3
HRQAIPESEAEDQER

MTSS1

686

O43312
VRIHVTVLDTNDNAP

PCDHGA9

226

Q9Y5G4
QVRVLDQNDHAPVLV

PCDH8

596

O95206
EHPNQEVVDNTRLES

KATNAL2

146

Q8IYT4
QHNDRIQPIILVADE

ENPP4

306

Q9Y6X5
RVLHALQEAAPEVVQ

DDX28

136

Q9NUL7
RQDLAIVEHTEPRVA

KDM4E

336

B2RXH2
SRTEHIQTPEADIVQ

KIAA2012

756

Q0VF49
LDEQLSQVREADRHP

JAKMIP3

246

Q5VZ66
ERRQPQEEVVHEDQG

LMO7

1321

Q8WWI1
IHPERESNQEDVLVR

LCA5L

476

O95447
VPNALRHAVDGRQEE

GLT8D1

51

Q68CQ7
LQLEIRAPTADEIHV

PRKCG

161

P05129
TQPSDQDTLVQRAEH

PDLIM5

396

Q96HC4
ARQQVHVELDVAKPD

GFAP

216

P14136
REAQEEVGLRPHQVE

NUDT7

91

P0C024
RAQELDALDNSHPIE

NPEPPSL1

406

A6NEC2
LQLESPHEERVSNAL

DGKH

1071

Q86XP1
RHLTQQDPLSEAIVE

MROH8

66

Q9H579
VLSLVDDPRNHIENQ

MRPL37

136

Q9BZE1
HERDTVPSVQDNDPI

GPR151

391

Q8TDV0
PELANAHNVIVTERV

DSG1

941

Q02413
DEISHIVNRIAPQDE

ETAA1

131

Q9NY74
VQVEIRVNDVNDHSP

DCHS2

151

Q6V1P9
IAVLDVNDNRPAIHV

DCHS2

401

Q6V1P9
FVRVDLEDVNDNHPV

DCHS2

756

Q6V1P9
VFHVDVEVRDINDNP

PCDHA4

116

Q9UN74
EAVLDVIPTDIHQRA

FBP1

301

P09467
EVTVVFEALHNLEPR

ITGA9

961

Q13797
DIIDPADHLTVRQQL

NPAS4

121

Q8IUM7
HEVRIVVRDRNDNSP

PCDH15

131

Q96QU1
EESENLHNADQPLRV

EIF3C

426

Q99613
REVQIHPDSDQISGL

FLT3

741

P36888
SSPQVQEHILEVERR

GAL3ST1

231

Q99999
LRPEVITDENLHDNI

DYNC2H1

81

Q8NCM8
IDFHNPADVVEIRTL

FKBP10

371

Q96AY3
NRSVQVVNLDPAAEH

GPN3

31

Q9UHW5
SPQASVVLEHREIAD

BRME1

476

Q0VDD7
DIVIRLPNLHNDSVV

CABIN1

661

Q9Y6J0
QLDEEEVLHSPRLTN

CARD14

51

Q9BXL6
AHEALPNRVTERTVD

IGHM

416

P01871
REVQLLRESDEHPNV

ERN1

611

O75460
VEPSEATNRSVQAHE

CENPC

101

Q03188
NTQHAVEAIRPREES

CEP63

301

Q96MT8
VEAQDVRAPAHAARA

FNDC1

1086

Q4ZHG4
NPESILDEHVQRVLR

AXIN1

466

O15169
EDHVQAQILPFREDS

CUL4A

111

Q13619
RLVQPQDRQDAVHAI

C3orf38

36

Q5JPI3
PEAQEEEIVHRSLNL

CMYA5

911

Q8N3K9
HDERIVIVAEQRPDS

DIP2C

836

Q9Y2E4
EIHVPEEQAARELIT

DENND4C

931

Q5VZ89
LIVIPRSQEDDAHNV

CEP95

51

Q96GE4
QEAVRREHQEASVPK

HASPIN

306

Q8TF76
RESNEVVHLEAQNDP

MARCHF7

426

Q9H992
HRLLAEQEVLAPQVV

MAN2B1

856

O00754
QDHPEVNSLEEVVRL

ME3

391

Q16798
VHSDEDNPERIQQII

LYRM9

46

A8MSI8
IHAEESTIPANLERL

DNAI4

461

Q5VTH9
PDINSTVEHDENRTI

KMT2A

2081

Q03164
PAQSDRLANHQEDDV

GRB10

36

Q13322
SQAVEEVTERDHPLV

CUL9

706

Q8IWT3
RPVQHREVQGNESDL

CAPG

91

P40121
ISEQELHPVSARARV

ITGA7

831

Q13683
AAHQQLRETDIPQLS

HOMEZ

471

Q8IX15
VHLDDPERAIQDAIL

DNAAF5

796

Q86Y56
HDDRIVLVAEQRPDA

DIP2A

851

Q14689
PAVVLAILARNAEHS

CERCAM

31

Q5T4B2
ALERHVIQAVNTSPE

HPS1

186

Q92902
VLLAAHPDAQAEVRL

BCAM

21

P50895
NQREEAVHDQRERAP

CCDC8

406

Q9H0W5
SHIIDQARVEQVPES

DNAH2

2856

Q9P225
RTSHPQDVIEDLSQN

SLC12A6

81

Q9UHW9
SEQEEHELPVLSRQA

SASH3

131

O75995
LRSVIAHIEDPEDTN

S100PBP

326

Q96BU1
HIERQEDSPINSVSA

DSEL

586

Q8IZU8
RAQELDALDNSHPIE

NPEPPS

406

P55786
HVSAQLERVRVSPQD

CTNND1

36

O60716
AHVTINARAEEDVEP

DBNL

111

Q9UJU6
HPEAIRAVREEATQV

CYP8B1

301

Q9UNU6
VELIHPSQDEDRQSN

PPP6R2

196

O75170
QAREAELQAVLHPEF

TBRG4

421

Q969Z0
EAAVQPHSRARQEQL

LIMCH1

336

Q9UPQ0
EEPRAVHAALQRANS

MICAL2

1221

O94851
LLVVHAVDQDQRPVL

MTMR3

396

Q13615
QQVDEEFLRSDHPAI

PDGFRB

971

P09619
VNLEHLRIDVVSENP

FBXL21P

256

Q9UKT6
HAVVNEDPNARIIRD

KIF13B

356

Q9NQT8
SEHLSVRPQTALEEN

MRPS23

151

Q9Y3D9
QIEEAVEAAINRHRP

QARS1

121

P47897
EKDNDHSRPDIQVQA

RARS2

51

Q5T160
VATHLQTAPELVDRV

UTP11

151

Q9Y3A2
RLEAGPESQHQTREQ

TRIM40

156

Q6P9F5
TPVESQQHEIESRIL

STAT2

136

P52630
EHDISATVQPEDARV

PRUNE2

1666

Q8WUY3
DRDNHVTIIRENIQP

TLL1

256

O43897
QASDHRPVLAIVEVE

SYNJ2

851

O15056
DESPVARERNVIVHT

NHS

416

Q6T4R5
QRATIDPELNEIHVL

MKLN1

516

Q9UL63
RETVSPQDIVQDAIH

TMEM184A

351

Q6ZMB5
AVEAVLLESIHRFNP

SAMD9

1066

Q5K651
ERNPQARISAAHEAL

ST7

196

Q9NRC1
GNREPEIQETLQSEH

STXBP5

31

Q5T5C0
AVDRHPTDININLTI

HHIP

436

Q96QV1
QAPVDDAQEILHSRF

SEC23A

686

Q15436
ANEAINTREPAAEIE

SCRN1

91

Q12765
REVHPIQAQVESLER

SPTBN5

2411

Q9NRC6
HPDQAQAILSRLAEI

SPTBN1

1026

Q01082
VQRVQVLPDADTLLH

APC

1476

P25054
HLLREVTVEENNASP

CEP164

1041

Q9UPV0
HVQRDAVRTVALNAP

C12orf50

336

Q8NA57
NFAERHILPAELEEQ

C12orf76

71

Q8N812
EQLRDVPIDHSDLVA

CLASP1

1291

Q7Z460
NENPDTLHQDIQEVR

CLVS2

21

Q5SYC1
HLTDQDNEIRATDLP

SUPT6H

281

Q7KZ85
QAPELDEHLVERATQ

USP17L3

416

A6NCW0
RVLQERVTPQDALHE

ZNF599

166

Q96NL3
QEHRPESSEEAAALV

ZSCAN2

111

Q7Z7L9
QEAAVELSQLRDPQH

UQCRFS1

186

P47985
AVNAVRHVQDPLAAA

PHLPP2

996

Q6ZVD8
EQLIQERRSHEVNPA

TNFSF14

81

O43557
PRTAQEVAELIDQHE

PLEKHG4B

376

Q96PX9
HVSFQDEDEIVRINP

SPRED1

236

Q7Z699
QLQQSLHTRAEAEAP

ZSCAN1

181

Q8NBB4
QAPELDEHLVERATQ

USP17L18

416

D6R9N7
VDNRELEQHIQTSDP

USP47

921

Q96K76
QAPELDEHLVERATQ

USP17L5

416

A8MUK1
HCTQESRRELPEQEV

TXLNGY

61

Q9BZA5
QAPELDEHLVERATQ

USP17L21

416

D6R901
QAPELDEHLVERATQ

USP17L13

416

C9JLJ4
AAQEELEVIATHPAR

VIT

631

Q6UXI7
RQQHPESGEEAVALV

SCAND2P

106

Q9GZW5
QAPELDEHLVERATQ

USP17L19

416

D6RCP7
QAVEENIHDDPIRLF

TRAT1

161

Q6PIZ9
NIASHEPRIQEITER

SPTA1

841

P02549
QAPELDEHLVERATQ

USP17L1

416

Q7RTZ2
QDVTLHDLDVANARP

RUVBL1

236

Q9Y265
ELQARVQEHHPESRE

ZSCAN26

106

Q16670
QAPELDEHLVERATQ

USP17L12

416

C9JPN9
RHLEGTNEVAQPSRE

TOPORS

801

Q9NS56
QAPELDEHLVERATQ

USP17L24

416

Q0WX57
DERHSRICPENNEVD

ZNF432

71

O94892
SDLQEVRDVHIPSNV

ZZEF1

326

O43149
QVPELDEHLVERATQ

USP17L7

416

P0C7H9
SVAPQERSHNVIEVA

PHLPP1

1626

O60346
ERSHNVIEVATDAPL

PHLPP1

1631

O60346
AAQENRPVTDHLDEQ

TBCD

636

Q9BTW9
RPVTDHLDEQAVQGL

TBCD

641

Q9BTW9
EAAVELSQLRDPQHD

UQCRFS1P1

196

P0C7P4
VHPDISEELNRQLED

TXLNB

51

Q8N3L3
LHPRENDQLDFIVET

TRIM2

291

Q9C040
HSVLEPEANQIRASI

TRIM23

216

P36406
QPAQAEEAAEHSRVL

TIGD5

496

Q53EQ6
PVETHELIRNAADIS

SLC5A1

16

P13866
QAPELDEHLVERATQ

USP17L22

416

D6RA61
QAPELDEHLVERATQ

USP17L15

416

C9J2P7
QAPELDEHLVERATQ

USP17L17

416

D6RBQ6
LQHAISVPEDVARDL

TG

581

P01266
VTDHDIPQQLVERLQ

USP7

531

Q93009
APAEQRPHQEEELQT

ZNF202

186

O95125
VEPEEHQQTLQRVRE

UNC13D

91

Q70J99
LRAAHVPENSDTEQD

ZNF106

1361

Q9H2Y7
EQEVAADETRNLPHS

TOE1

381

Q96GM8
DATPQDQAVLHRNRA

UNC45A

51

Q9H3U1
QAPELDEHLVERATQ

USP17L20

416

D6RJB6
TSPIVDTDHQLLRDN

TNRC6B

1511

Q9UPQ9
QAPELDEHLVERATQ

USP17L10

416

C9JJH3
QAPELDEHLVERATQ

USP17L11

416

C9JVI0
EIQSRVQELHPESGE

ZNF263

96

O14978
TLEAIIREAENIPVH

KDM5C

1001

P41229
ELQVLDAEGNRVEHP

KCNF1

206

Q9H3M0
DAEGNRVEHPTLENV

KCNF1

211

Q9H3M0
RSIHVIQDLVNEEPR

LRRC51

21

Q96E66
PADTRDNEVNHALEQ

MYPN

216

Q86TC9